MXPA06009336A - Substituted azetidine compounds, their preparation and use as medicaments - Google Patents

Abstract

The present invention relates to substituted Azetidine compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.

Description

SUBSTITUTED AZETIDINAL COMPOUNDS, ITS PREPARATION AND ITS APPLICATION AS MEDICINES FIELD OF THE INVENTION The present invention relates to substituted azetidine compounds of general formula (I), to methods for their preparation, to medicaments comprising these compounds as well as to their use for the preparation of a medicament for the treatment of humans and animals. . BACKGROUND OF THE INVENTION Cannabinoids are compounds derived from the plant cannabis sativa, generally known as marijuana. The most active chemical compound in cannabinoids of natural origin is tetrahydrocannabinol (THC), particularly? 9-THC. These cannabinoids of natural origin, as well as their synthetic analogs, promote their physiological effects through the binding to receptors coupled to protein G, the so-called cannabinoid receptors. Currently, two clear types of receptors that bind to both natural and synthetic cannabinoids have been identified and cloned. These receptors, designated CBi and CB2, are involved in a series of physiological and physiopathological processes in humans and animals, eg. processes related to the central nervous system, immune system, cardiovascular system, endocrine system, respiratory system, gastrointestinal tract or reproduction, as described by e. in Hollister, Pharm. Rev. 38, 1986, 1-20; Reny and Singha, Prog. Drug. Res., 36, 71-114, 1991; Consroe and Sandyk, in Marijuana / Cannabinoids, Neurobiology and Neurophysiology, 459, Murphy L. and Barthe A. Eds., CRC Press, 1992. Therefore, compounds that have high binding affinity to these cannabinoid receptors and that are suitable to modulate these receptors are useful for the prevention and / or treatment of disorders related to cannabinoid receptors. SUMMARY OF THE INVENTION Accordingly, an object of the present invention was to provide new compounds suitable, in particular, as active substances in medicaments, preferably in drugs for the modulation of cannabinoid receptors, particularly cannabinoid receptors 1 (CBi). Preferably said medicaments should be suitable for the prophylaxis and / or treatment of disorders related to the central nervous system, the immune system, the cardiovascular system, the endocrine system, the respiratory system, the gastrointestinal tract or the reproduction in humans and / or animals. .

Said objective was achieved by providing the substituted azetidine compounds of general formula I presented below, stereoisomers, corresponding N-oxides, corresponding salts and corresponding solvates. Surprisingly, it has been observed that these compounds have a high affinity for cannabinoid receptors, particularly for the CBi receptor and are therefore suitable for the prophylaxis and / or treatment of various disorders related to the central nervous system, the immune system, the immune system, and the immune system. cardiovascular, the endocrine system, the respiratory system, the gastrointestinal tract or the reproduction in humans and / or animals, preferably humans including newborns, children and adults. Accordingly, in one of its aspects, the present invention relates to substituted azetidine compounds of general formula I, wherein R1 represents an optionally at least monosubstituted phenyl group, R2 represents a cycloaliphatic, saturated or unsaturated group, which may be optionally at least monosubstituted, optionally containing at least one heteroatom as ring member, which may be fused to an optionally at least monosubstituted mono- or polycyclic ring system, or an optionally at least monosubstituted aryl or heteroaryl group, which may be fused with an optionally at least monosubstituted mono- or polycyclic ring system, R3 represents a straight or branched aliphatic group, saturated or unsaturated, optionally at least monosubstituted, a cycloaliphatic, saturated or unsaturated group, which may optionally be at least monosubstituted, optionally containing at least one heteroatom as ring member, which may be fused with a mono ring system or polycyclic and / or linked via a linear or branched alkylene group, or an optionally at least monosubstituted aryl or heteroaryl group, which may be fused with a mono- or polycyclic ring system and / or linked via a straight or branched alkylene group, with the proviso that R3 is linked to the azetidine ring through a carbon atom, R4 represents a hydrogen atom, a cyano group, a carboxy group, a linear or branched alkyl group, or an optionally at least monosubstituted aryl group , R5 represents a group -0-S02-R6, a group -NH-CO-R7, a group -NH2 / a group -NH-S02-R8, a group -NR9-S02-R10 or a group -O-CO -R11, R6 repres a linear or branched, saturated or unsaturated aliphatic group, optionally at least monosubstituted, a cycloaliphatic, saturated or unsaturated group, which may optionally be at least monosubstituted, optionally containing at least one heteroatom as ring member, which may be condensed with a mono- or polycyclic ring system and / or linked via a linear or branched alkylene group, or an optionally at least monosubstituted aryl or heteroaryl group, which may be fused with a mono- or polycyclic ring system and / or linked via a linear or branched alkylene group, R7 represents a linear or branched, saturated or unsaturated aliphatic group, optionally at least monosubstituted, a cycloaliphatic, saturated or unsaturated group, which may optionally be at least monosubstituted, optionally containing at least one heteroatom as member of the ring, which may be condensed with a mono- or ring system polycyclic and / or linked via a linear or branched alkylene group, or an optionally at least monosubstituted aryl or heteroaryl group, which may be fused with a mono- or polycyclic ring system and / or linked via a straight or branched alkylene group, R8 represents a linear or branched, saturated or unsaturated aliphatic group, optionally at least monosubstituted, a cycloaliphatic, saturated or unsaturated group, which may optionally be at least monosubstituted, optionally containing at least one heteroatom as ring member, which may be condensed with a mono- or polycyclic ring system and / or linked via a linear or bridged alkylene group, and / or bridged by a linear or branched alkylene group, or an optionally at least monosubstituted aryl or heteroaryl group , which may be condensed with a mono- or polycyclic ring system and / or linked via a linear or branched alkylene group or, R9 represents a -S02-R12 group, a -CO-R13 group, a linear or branched, saturated or unsaturated aliphatic group, optionally at least monosubstituted, a saturated or unsaturated cycloaliphatic group, which may optionally be at least monosubstituted , optionally containing at least one heteroatom as a ring member, which may be fused with a mono- or polycyclic ring system and / or linked via a straight or branched alkylene group and / or be in bridged form by a linear alkylene group or branched, or an optionally at least monosubstituted aryl or heteroaryl group, which may be fused with a mono- or polycyclic ring system and / or linked via an alkylene group, R10 represents a linear or branched, saturated or unsaturated aliphatic group, optionally at least monosubstituted, a cycloaliphatic, saturated or unsaturated group, which may optionally be at least monosubstituted, optionally containing at least a heteroatom as a member of the ring, which may be condensed with a mono- or polycyclic ring system and / or linked via a linear or bridge-shaped alkylene group, and / or be in the form of a bridge by a linear or branched alkylene group, or an optionally at least monosubstituted aryl or heteroaryl group, which may be fused with a mono- or polycyclic ring system and / or linked via a linear alkylene group or branched, R11 represents a linear or branched, saturated or unsaturated aliphatic group, optionally at least monosubstituted, a cycloaliphatic, saturated or unsaturated group, which may optionally be at least monosubstituted, optionally containing at least one heteroatom as ring member, which may be fused with a mono- or polycyclic ring system and / or linked via a linear or bridged alkylene group, and / or be bridged by a straight or branched alkylene group, or an aryl or heteroaryl group optionally at least monosubstituted, which may be fused with a mono- or polycyclic ring system and / or linked via a linear alkylene group or branched, R12 represents a linear or branched aliphatic, saturated or unsaturated, optionally at least monosubstituted, a saturated or unsaturated cycloaliphatic group, which may be optionally at least monosubstituted, optionally containing at least one heteroatom as ring member, which may be condensed with a mono- or polycyclic ring system and / or linked via a linear or bridged alkylene group, and / or be bridged by a linear or branched alkylene group, or an aryl or heteroaryl group optionally at least monosubstituted, which may be fused with a mono- or polycyclic ring system and / or linked via a linear or branched alkylene group, R13 represents a linear or branched, saturated or unsaturated aliphatic group, optionally at least monosubstituted, a cycloaliphatic group , saturated or unsaturated, which may optionally be at least monosubstituted, optionally containing less a heteroatom as a ring member, which may be fused with a mono- or polycyclic ring system and / or linked via a linear or bridged alkylene group, and / or be bridged by a linear alkylene group or branched, or an optionally at least monosubstituted aryl or heteroaryl group, which may be fused with a mono- or polycyclic ring system and / or linked via a straight or branched alkylene group, optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, their racemate or in the form of a mixture of at least two of their stereoisomers, preferably enantiomers and / or diastereomers, in any mixture ratio, or one of its corresponding N-oxides, one of its corresponding salts, or one of its corresponding solvates, with the proviso that compounds of general formula I, in which R1 and R2 each represent an unsubstituted phenyl group, R5 represents a group -0-S02-R6 and R6 represents a methyl group, are excluded. DETAILED DESCRIPTION OF THE INVENTION A mono- or polycyclic ring system according to the present invention means a mono- or polycyclic hydrocarbon ring which can be saturated, unsaturated or aromatic. If the ring system is polycyclic, each of its different rings may show a different degree of saturation, that is, it may be saturated, unsaturated or aromatic. Optionally each of the rings of the mono- or polycyclic ring system may contain one or more, ie, 1, 2 or 3 heteroatoms as ring members, which may be identical or different and which can preferably be selected from the group consisting of N, O, S and P, more preferably selected from the group consisting of N, O and S. Preferably the polycyclic ring system can comprise two rings that are fused. The rings of the mono- or polycyclic ring system preferably have 5 or 6 members. The term "condensate", according to the present invention, means that a ring or an annular system is joined to another annular ring or system, whereby the terms "ringed" or "aneled" are also used by those skilled in the art to designate this type of joint. If one or more of the residues R2, R3 and R6-R13 represents or comprises a cycloaliphatic, saturated or unsaturated group, optionally containing at least one heteroatom as ring member, which may be substituted by one or more, i.e. 1, 2, 3, 4 or 5 substituents, unless otherwise defined, each substituent can be independently selected from the group consisting of hydroxy, fluorine, chlorine, bromine, linear or branched C? _ Alquilo alquiloalkyl, C alco-linear alkoxy or branched, linear or branched perfluoroalkoxy C? _4 linear or branched, perfluoroalkyl C? _4 linear or branched, oxo, amino, carboxy, amido, cyano, nitro, S02NH2, alkyl -CO-C? _4, alkyl -SO-Ca_4, alkyl -S02- C? -4, alkyl -NH-SO2-C1-4, in which the C? _ Alkyl may in each case be linear or branched, and a phenyl group, more preferably be selected from the group consisting of hydroxy, F, Cl , Br, methoxy, ethoxy, methyl, ethyl, oxo, CF 3 and a phenyl group. If one or more of the residues R2, R3 and R6-R13 represents or comprises a cycloaliphatic group, which contains one or more heteroatoms as ring members, unless otherwise defined, each of these heteroatoms may preferably be selected from the group which consists of N, O and S. Preferably a cycloaliphatic group may contain 1, 2 or 3 heteroatoms independently selected from the group consisting of N, O and S. Suitable cycloaliphatic, saturated or unsaturated groups, which may be optionally at least monosubstituted optionally containing at least one heteroatom as ring member, can preferably be selected from the group consisting of Cyclopropyl, Cyclobutyl, Cyclopentyl, Cyclohexyl, Cycloheptyl, Cyclooctyl, Cyclopentenyl, Cyclohexenyl, Cycloheptenyl, Cyclooctenyl, Pyrrolidinyl, Piperidinyl, Piperazinyl, Homo-Piperazinil and Morpholinil. If one or more of the residues R2, R3 and R6-R13 comprises a mono- or polycyclic ring system, which is substituted by one or more, ie 1, 2, 3, 4 or 5 substituents, unless the otherwise, each substituent can be independently selected from the group consisting of hydroxy, fluorine, chlorine, bromine, linear or branched Ca.sub.4 alkoxy, straight or branched Ca.sub.4 alkyl, linear or branched perfluoroalkoxy Ca.sub.4 straight or branched, linear or branched C 1-4 perfluoroalkyl, amino, carboxy, oxo, amido, cyano, nitro, -S02NH2, alkyl -CO-C? -4, alkyl -SO-C? -4, alkyl -S02-C? _4, alkyl -NH-S02-C? _4, in wherein the C C4 alkyl may in each case be linear or branched, and a phenyl group, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methyl, ethyl, methoxy, ethoxy, CF3, oxo and a phenyl group. If one or more of the residues R2, R3, R4 and R6-R13 comprises an aryl group, which is substituted by one or more, ie 1, 2, 3, 4 or 5 substituents, unless otherwise defined, each substituent can be independently selected from the group consisting of a halogen atom, a linear or branched C6 alkyl group, a linear or branched C6-6 alkoxy group, a formyl group, a hydroxy group, a trifluoromethyl group, a trifluoromethoxy group, a alkyl group -CO-C-6, a cyano group, a carboxy group, an alkyl group -CO-0-C? -6, a -CO-NRARB group, a -CO-? H-? RcRD group, a group alkyl S-Cx-6, an alkyl group -SO-C? _6, an alkyl group -S02-C? -6, an alkylene group -C? -6-alkyl SC? _e, an alkylene group -Ca_6-alkyl SO -C? _6, an alkylene-C? _6-alkyl group S02-C? _6, a C1_6 alkyl group substituted by one or more hydroxy groups and an alkylene group -C_6-? RERF, in which RA, RB, identical or different, represent hydrogen or a C? _6 alkyl group, or RA and RB together with the nitrogen bridge atom form a heterocyclic ring system of 3-10 members, mono- or bicyclic, saturated, which may be at least monosubstituted by one or more C? -6 alkyl groups identical or different and / or which may contain at least one additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur as ring member, Rc , RD, identical or different, represent a hydrogen atom, a C? _6 alkyl group, a C0-0-C? -6 alkyl group, a C3-8 cycloalkyl group, an C? _6-cycloalkyl C3- 8, an alkylene group C? S-alkyl 0-C6-6 or a C6-6 alkyl group substituted by one or more hydroxy groups, or Rc, RD together with the nitrogen bridge atom form a heterocyclic ring system of 3 to 10 members, mono- or bicyclic, saturated, which may be at least monosubstituted by one or more substituents independently selected from the group consisting of a C? _6 alkyl group, an alkyl group -CO-C? _6, a group alkyl -CO-O-Cx_6, an alkyl group -CO-NH-C? _6, an alkyl group -CS-NH-C? _6, an oxo group, a group C? -6 alkyl substituted by one or more hydroxy groups, an alkylene group C? _6-alkyl 0-C_6 and a group -CO-NH2 and / or which may contain at least one additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur as a member of the ring, and in which RE, RF, identical or different, represent hydrogen or a C? _6 alkyl group, or RE and RF together with the nitrogen bridge form a heterocyclic ring system from 3 to 10 members, mono- or bicyclic, saturated, which may be at least monosubstituted by one or more C? _6 alkyl groups identical or different and / or which may contain at least one additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur as member of the ring. Preferred aryl groups, which may be at least optionally monosubstituted, are phenyl and naphthyl. If one or more of the residues R2, R3 and R6-R13 represents or comprises a heteroaryl group, which is substituted by one or more, ie 1, 2, 3, 4 or 5 substituents, unless otherwise defined, each substituent may be independently selected from the group consisting of a halogen atom, a linear or branched Cx_6 alkyl group, a linear or branched C? ~ 6 alkoxy group, a formyl group, a hydroxy group, a trifluoromethyl group, a trifluoromethoxy group, a - C 1 -C 6 alkyl group, a cyano group, a carboxy group, an alkoyl group ~ CO-0-C? -6, a -CO-NR? RB group, a -C0-NH-NRcRD group, a alkyl group SC? _6, an alkyl group -SO-Cx-6, an alkyl group S02-C? -6, an alkylene group C? _6-alkyl SC? -6, an alkylene group C? _6-alkyl S0 ~ C ? -6, an alkylene group C? _6-alkyl S02-C. 6, a C? -6 alkyl group substituted by one or more hydroxy groups and an alkylene group -C? _6-NRERP, in which RA, RB, identical or different, represent hydrogen or a C? -6 alkyl group, or RA and RB together with the nitrogen bridge atom form a monocyclic or bicyclic, saturated, 3- to 10-membered heterocyclic ring system, which may be at least monosubstituted by one or more C? _6 alkyl groups identical or different and / or it can contain at least one additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur as ring member, Rc, RD, identical or different, represents a hydrogen atom, a C? _6 alkyl group, an alkyl group -CO- 0-C? _ 6, a C3-8 cycloalkyl group, a C? _6 alkylene group-C3_8 cycloalkyl, a C? -6 alkylene group-0-Ca_6 alkyl or a C? _6 alkyl group substituted by one or more hydroxy groups , or Rc, RD together with the nitrogen bridge atom form a heterocyclic ring system of 3 to 10 members, mono - or bicyclic, saturated, which may be at least monosubstituted by one or more substituents independently selected from the group consisting of a C? _6 alkyl group, an alkyl group -CO-C? ~ 6, an alkyl group -CO -O- C? .6, an alkoyl group -CO-NH-C? -6 / an alkyl group -CS-NH-Cx_6, an oxo group, a C? --6 alkyl group substituted by one or more hydroxy groups , an alkylene group C? _6-alkyl 0-C? -6 and a group -C0-NH2 and / or which may contain at least one additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur as ring member, and in which RE, RF, identical or different, represent hydrogen or a C? _6 alkyl group, or RE and RF together with the nitrogen bridge atom form a heterocyclic ring system of 3 to 10 members, mono- or bicyclic, saturated, which may be at least monosubstituted by one or more C? -6 alkyl groups identical or different and / or which may contain at least one additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur as ring member The heteroatoms, which are present as ring members in the heteroaryl radical, can, unless otherwise defined, be independently selected from the group consisting of nitrogen, oxygen and sulfur. Preferably a heteroaryl radical may contain 1, 2 or 3 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur. Suitable heteroaryl groups, which may be at least optionally unsubstituted, may preferably be selected from the group consisting of thienyl, furyl, pyrrolyl, pyridinyl, imidazolyl, pyrimidinyl, pyrazinyl, indolyl, quinolinyl, isoquinolinyl, benzo [1,2,5] thio diazolyl. , benzo [b] thiophenyl, benzo [b] furanyl, imidazo [2, lb] thiazolyl and pyrazolyl, more preferably from the group consisting of thienyl-, benzo [1,2, 5] -thiodiazolyl, benzo [b] thiophenyl, imidazo [2, lb] thiazolyl and pyrazolyl.

If one or more of the residues R3 and R6-R13 represents or comprises a linear or branched, saturated or unsaturated aliphatic group, which is substituted by one or more, ie 1, 2, 3, 4 or 5 substituents, unless to the contrary, each substituent may be independently selected from the group consisting of hydroxy, fluorine, chlorine, bromine, linear or branched C? _ alco alkoxy, linear or branched C? -4 perf perfluoroalkoxy, linear or branched C? -4 perf perfluoroalkyl, amino, carboxy, amido, cyano, nitro, -S02NH2, alkyl -CO-C? -. 4, alkyl -SO-C? -4, alkyl -S02-C? _4, alkyl -NH-S02-C? -4 , in which the C? alkyl it may in each case be linear or branched, and a phenyl group, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methoxy, ethoxy, CF3 and a phenyl group. Saturated or unsaturated, linear or branched aliphatic groups, which may be substituted by one or more substituents, may preferably be selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, vinyl, ethynyl, propenyl, propynyl, butenyl and butynyl. If any of the residues R3 and R6-R13 comprises a linear or branched alkylene group, unless otherwise defined, said alkylene group may be preferably selected from the group consisting of methylene (- (CH2) -), ethylene (- ( CH2) 2-), n-propylene (~ (CH2) 3-), isopropylene (- (C (CH3) 2-), n-butylene (- (CH2) 4-), n-pentylene (- (CH2) 5-), n-hexylene (- (CH2) 6-), n-heptylene (- (CH2) 7-), n-octylene (- (CH2) 8-), n-nonylene (~ (CH2) 9-) and n-decylene (- (CH2) 10-), more preferably from the group consists of (- (CH2) -), ethylene (- (CH2) 2-), n-propylene (- (CH2) 3-), isopropylene (- (C (CH3) 2-) and n-butylene (- ( CH2) 4-) Compounds of general formula I indicated above are preferred, wherein R1 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a halogen atom, a linear or branched C6-6 alkyl group, a linear or branched C6-6 alkoxy group, a formyl group, a hydroxy group, a trifluoromethyl group, a trifluoromethoxy group, a C0-C6 alkyl group, a cyano group, a carboxy group, an alkyl group -C0-0-C? -6, a group -C0-NRARB, a group -CO-NH-NR RD, an alkyl group SC? _6, an alkyl group -S0-C? _6 , an alkyl group -S02-C? _6, a group alkylene-C6-alkyl SC6, an alkylene group -C6-6-alkyl-SO-C6-6, an alkylene-C6-6-alkyl group -S02-C6, an alkyl group substituted by one or more hydroxy groups and an alkylene group -C? _6-? RERF, in which RA, RB, identical or different, represent hydrogen or a C? _6 alkyl group, or RA and RB together with the nitrogen bridge atom form a system heterocyclic ring of from 3 to 10 members, mono- or bicyclic, saturated, which may be at least monosubstituted by one or more C? -6 alkyl groups identical or different, and / or which may contain at least one additional heteroatom selected from the group consists of nitrogen, oxygen and sulfur as a member of the ring, Rc, RD, identical or different, represents a hydrogen atom, a C? -6 alkyl group, an alkyl group -CO-0-C? _ 6, a cycloalkyl group C3_8, a C6_6 alkylene group C3_8 cycloalkyl, a C6_6 alkylene group OC_6_6 alkyl or a C6_6 alkyl group substituted by one or more hydrocarbon groups oxy, or Rc, RD together with the nitrogen bridge atom form a saturated monocyclic or bicyclic 3- to 10-membered heterocyclic ring system, which may be at least monosubstituted by one or more substituents independently selected from the group consists of a C6_6 alkyl group, an alkyl group -CO-C6-6, an alkyl group -CO-O-Cx-6, an alkyl group -CO-NH- C6-6, an alkyl group -CS-NH - C? -6, an oxo group, an alkoyl group C? _6 substituted by one or more hydroxy groups, an alkylene group C-6- alkyl 0-C? -6 and a group -C0-NH2 and / or which can contain at least one additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur as ring member, and in which RE, RF, identical or different, represent hydrogen or a C? _6 alkyl group, or RE and RF together with the nitrogen bridge atom form a heterocyclic ring system of 3 to 10 members, mono- or bicyclic, saturated, which may be at least monosubstituted by one or more C? _6 alkyl groups identical or different and / or which may contain at least one additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur as ring member, preferably R1 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, an alkyl group C ? Linear or branched, a linear or branched C? _ Alkoxy group, a formyl group, a hydroxy group, a trifluoromethyl group, a trifluoromethoxy group, a cyano group and a carboxy group, more preferably R1 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a methoxy group, a trifluoromethyl group and a trifluoromethoxy group, more preferably still R1 represents a phenyl group, which is substituted by a chlorine atom at the 4-position, and the residues R2-R13 have the meaning, indicated above, optionally in the form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemate or in the form of a mixture of at least two of their stereoisomers, preferably enantiomers and / or diastereomers, in any mixture ratio, or one of their corresponding N-oxides, one of their corresponding salts, or one of their corresponding solvates. Also preferred is the compounds of general formula I indicated above, wherein R 2 represents a saturated or unsaturated C 3-8 cycloaliphatic group, which may optionally be at least monosubstituted, optionally containing at least one heteroatom as ring member, which may be condensed with an optionally at least monosubstituted mono- or polycyclic ring system, or a 5- or 6-membered aryl or heteroaryl group, optionally at least monosubstituted, which may be fused with a mono- or polycyclic ring system optionally at least monosubstituted, preferably R 2 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a halogen atom, a linear or branched C 1-6 alkyl group, a linear C 1-6 alkoxy group or branched, a formyl group, a hydroxy group, a trifluoromethyl group, a trifluoromethoxy group, an alkali group the -CO-C? _6, a cyano group, a carboxy group, an alkyl group -CO-0-C? _e, a -C0-NRARB group, a -CO-NH-NRcRD group, an SC? _6 alkyl group , an alkyl group -SO-C? _6, an alkyl group -S02-C? _6, an alkylene group -C? -6-alkyl SC? -6, an alkylene group -C? _6-alkyl -SO-C? _6, an alkylene group -C? _6-alkyl -S02-C? _6, a C6 alkyl group substituted by one or more hydroxy groups and an alkylene group -C? _6-NRER, in which RA, RB, identical or different , represent hydrogen or a Cx_6 alkyl group, or RA and RB together with the nitrogen bridge atom form a saturated, mono- or bicyclic, 3- to 10-membered heterocyclic ring system, which may be at least monosubstituted by one or more alkyl groups C? -6 identical or different and / or which may contain at least one additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur as ring member, Rc, RD, identical or different, represents a hydrogen atom, a group C alkyl x-6, an alkyl group -CO-0-C? 6 / a C3_8 cycloalkyl group, a C3_6 alkylene group, a C3_8 cycloalkyl group, an alkylene group C6_6 alkyl 0-C? -6 or a group C? _6 alkyl substituted by one or more hydroxy groups, or Rc, RD together with the nitrogen bridge atom form a saturated monocyclic or bicyclic 3- to 10-membered heterocyclic ring system, which may be at least monosubstituted by one or more substituents independently selected from the group consisting of in a C? -6 alkyl group, an alkyl group -CO-C? -6, an alkyl group -CO-O-C_e, an alkyl group -CO-NH-C? -6, an alkyl group -CS-NH - C? _6, an oxo group, a C? _6 alkyl group substituted by one or more hydroxy groups, an alkylene group C? -6-alkyl-0-C-6 and a group -CO-NH2 and / or which can contain at least one additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur as ring member, and in which RE, RF, identical or different, represent hydrogen or a C? -6 alkyl group, or RE and RF together with the nitrogen bridge atom they form a heterocyclic ring system of 3-10 members, mono- or bicyclic, saturated, which can be at least monosubstituted by one or more groups. The C? -6 alkyl is identical or different and / or can contain at least one additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur as ring member, more preferably R2 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a methoxy group, a trifluoromethyl group and a trifluoromethoxy group, more preferably still R2 represents a phenyl group, which is substituted by a chlorine atom in the 4-position, and R1 and R3-R13 have the meaning indicated above, optionally in the form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any mixture ratio, or one of its corresponding N-oxides ntes, one of its corresponding salts, or one of its corresponding solvates. Also preferred are compounds of general formula I indicated above, in which R3 represents a linear or branched, saturated or unsaturated, optionally at least monosubstituted C?-Α 0 aliphatic group, a saturated or unsaturated C3_8 cycloaliphatic group, which may be optionally at least monosubstituted, optionally containing at least one heteroatom as a ring member, which may be fused with a mono- or polycyclic ring system and / or may be linked via a linear or branched C? -6 alkylene group, or a 5 or 6 membered aryl or heteroaryl group, optionally at least monosubstituted, which may be fused with a mono- or polycyclic ring system and / or may be linked via a straight or branched C6-6 alkylene group, preferably R3 represents an alkyl group Linear or branched, optionally at least monosubstituted, or a 5- or 6-membered aryl or heteroaryl group, optionally at least monosubstituted, which may be condensed with a mono- or polycyclic ring system and / or may be linked via a straight or branched C6-6 alkylene group, more preferably R3 represents a linear or branched, unsubstituted, C? _10 alkyl group, more preferably still R3 represents a methyl group, and R1, R2 and R4-R13 have the meaning indicated above, optionally in the form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemate or in the form of a mixture of at least two of their stereoisomers, preferably enantiomers and / or diastereomers, in any mixture ratio, or one of its corresponding N-oxides, one of its corresponding salts, or one of its corresponding solvates. Other preferred compounds of general formula I indicated above are compounds in which R4 represents a hydrogen atom, a cyano group, a carboxy group, a linear or branched C? _? Alquilo alkyl group, or a 5 or 6 membered aryl group, optionally at least monosubstituted, preferably R4 represents a hydrogen atom, a linear or branched C? _3 alkyl group, or an optionally at least monosubstituted phenyl group, more preferably R 4 represents a hydrogen atom or a linear C?-3 alkyl group or branched, more preferably still R4 represents a hydrogen atom, and R1-R3 and R5-R13 have the meaning indicated above, optionally in the form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemate or as a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any mixing ratio, or one of its corresponding N-oxides, one of its corresponding salts, or one of its corresponding solvates. Also preferred are compounds of general formula I indicated above, in which R 5 represents a group -0-S0-R 6, a group -NH-CO-R 7, a group -NH 2, a group -NH-S02-R 8 or a group -NR9-S02-R10, preferably R5 represents a group -0-S02-R6, a group -NH-S02-R8 or a group -NR9-S02-R10, and R1-R4 and R6-R13 have the meaning indicated above, optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any mixture ratio, or one of its N - corresponding oxides, one of their corresponding salts, or one of their corresponding solvates. Also preferred are compounds of general formula I indicated above, in which R6 represents a linear or branched, saturated or unsaturated, optionally at least monosubstituted C? _?? Aliphatic group, a cycloaliphatic, saturated or unsaturated group, which may be optionally at least monosubstituted, optionally containing at least one heteroatom as a ring member, which may be fused with a mono- or polycyclic ring system and / or may be linked via a linear or branched C? -6 alkylene group, or a optionally at least monosubstituted aryl or heteroaryl group of 5 or 6 membered, which may be fused with a mono- or polycyclic ring system and / or may be linked via a linear or branched Cx_6 alkylene group, preferably R6 represents a C3-8 cycloaliphatic group optionally at least monosubstituted or an optionally at least monosubstituted phenyl group, in which the respective substituents are selected independently of the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a linear or branched C? _6 alkyl group, a linear or branched C? -6 alkoxy group, a formyl group, a hydroxy group , a trifluoromethyl group, a trifluoromethoxy group, a cyano group and a carboxy group, more preferably R6 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a methoxy group, a trifluoromethyl group and a trifluoromethoxy group, and Rx-R5 and R7-R13 have the meaning indicated above, optionally in the form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemate or in the form of a mixture of at least two of their stereoisomers, preferably enantiomers and / or diastereomers, in any mixing ratio, or one of their N-oxides corr spondientes, one of its corresponding salts, or one of its corresponding solvates. In addition, the compounds of general formula I indicated above are preferred, in which R7 represents a linear or branched, saturated or unsaturated, optionally at least monosubstituted, C7-linear aliphatic group, a C3-8 cycloaliphatic group, saturated or unsaturated, which it may optionally be at least monosubstituted, optionally containing at least one heteroatom as ring member, which may be fused with a mono- or polycyclic ring system and / or may be linked via a linear or branched C6-6 alkylene group, or an optionally at least monosubstituted aryl or heteroaryl group, which may be fused with an annular system mono- or polycyclic and / or can be linked via a straight or branched C6-6 alkylene group, preferably R7 represents a linear or branched, optionally at least monosubstituted C5.5 alkyl group, a saturated C5-6 cycloaliphatic group, optionally at less monosubstituted, or an optionally at least monosubstituted phenyl group, more preferably R7 represents a linear or branched C? _5 alkyl group, optionally at least monosubstituted, a saturated C5_6 cycloaliphatic group, optionally at least monosubstituted, or an optionally at least monosubstituted phenyl group , in which, in each case, the substituents are selected, independently of one another, from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a methoxy group, a trifluoromethyl group and a trifluoromethoxy group, and R1-R6 and R8-R13 have the meaning indicated above, optionally in the form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemate or in the form of a mixture of at least two of their stereoisomers, preferably enantiomers and / or diastereomers, in any mixture ratio, or one of their corresponding N-oxides, one of their corresponding salts, or one of their corresponding solvates.

Also preferred are compounds of the general formula I indicated above, in which R8 represents an aliphatic group C? -? Or linear or branched, saturated or unsaturated, optionally at least monosubstituted, a C3_8 cycloaliphatic group, saturated or unsaturated, which may be optionally at least monosubstituted, optionally containing at least one heteroatom as a ring member, which may be fused with a mono- or polycyclic ring system and / or may be linked via a linear or bridged C 1 to C 10 alkylene group and / or it may be in the form of a bridge by a linear or branched C? _ al alkylene group, or an optionally at least monosubstituted 5 or 6-membered aryl or heteroaryl group, which may be fused with a mono- or polycyclic ring system and / or it can be linked via a linear or branched aliphenylene group, preferably R8 represents a linear or branched C? _10 alkyl group, a C5-6 cycloaliphatic group, or unsaturated, which may optionally be at least monosubstituted, optionally containing at least one heteroatom as ring member, which may be fused with a mono- or polycyclic ring system and / or may be linked via an alkylene group C? _3 linear or bridge-shaped and / or may be in the form of a bridge by a linear or branched C 1 -C 3 alkylene group, or an optionally at least monosubstituted 5 or 6-membered aryl or heteroaryl group, which may be fused to a system ring mono- or polycyclic and / or can be linked via a linear or branched C? -3 alkylene group, more preferably R8 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group, a phenyl group optionally at least monosubstituted, an optionally at least monosubstituted benzyl group, an optionally at least monosubstituted naphthyl group, which may be linked via an alkylene group C ?_3, an optionally at least monosu thienyl group substituted, an optionally at least monosubstituted group 2, 1,3-Benzothiadiazole, an optionally at least monosubstituted Benzo [b] thiophenyl group, an Imidazo group [2. lb] thiazole optionally at least monosubstituted, an optionally at least monosubstituted lH-pyrazole group or a 7,7-Dimethyl-2-oxo-bicyclo- [2.2.1] -hept-1-yl group, more preferably still R8 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group, an optionally at least monosubstituted phenyl group, an optionally at least monosubstituted benzyl group, an optionally at least monosubstituted naphthyl group, which can be linked via an alkylene group C? -3, an optionally at least monosubstituted thienyl group, an optionally at least monosubstituted 2,1,3-Benzothiadiazole group, an optionally at least monosubstituted Benzo [b] thiophenyl group, an Imidazo [2. lb] thiazole optionally at least monosubstituted, an optionally at least monosubstituted lH-pyrazole group or a 7,7-Dimethyl-2-oxo-bicyclo- [2.2.1] -hept-1-yl group, in which said substituents, if they are present, they are identical or different and are selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a formyl group, a phenyl group, a phenoxy group, a phenoxy group substituted by bromine in the 4-position and a methylsulfonyl group, and Rx-R7 and R9-R13 have the meaning indicated above, optionally in the form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemate or in the form of a mixture of minus two of its stereoisomers, preferably enantiomers and / or diastereomers, in any mixing ratio, or one of its corresponding N-oxides, one of its corresponding salts, or one of its corresponding solvates. Also preferred are compounds of general formula I indicated above, in which R9 represents a group -S02-R12, a group -CO-R13, a linear or branched, saturated or unsaturated aliphatic C? _? 0 group, optionally at least monosubstituted, a saturated or unsaturated C3-8 cycloaliphatic group, which may optionally be at least monosubstituted, optionally containing at least one heteroatom as ring member, which may be fused with a mono- or ring system polycyclic and / or can be linked by a straight or branched Cx_6 alkylene group and / or in bridging form by a linear or branched C6-6 alkylene group, or an optionally at least monosubstituted aryl or heteroaryl group, which may be fused to a mono- or polycyclic ring system and / or can be linked via an algerylene group C? -5, preferably R9 represents a group -S02-R12, a linear or branched C? -10 alkyl group, or an optionally at least monosubstituted phenyl group , which can be linked via an alkylene group C? .2 / more preferably R9 represents a group -S02-R12, a linear or branched C? _3 alkyl group, or a phenyl group, which can be linked via a group alkylene C? _2 and / or be substituted by one or more substituents independently selected from the group consisting of a fluorine atom, a chlorine atom and a bromine atom, and Rx-R8 and R10-R13 have the meaning previously indicated optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any mixture ratio, or one of its N - corresponding oxides, one of their corresponding salts, or one of their corresponding solvates. Also preferred are the compounds of general formula I indicated above, in which R 10 represents a linear or branched, saturated or unsaturated, optionally at least monosubstituted C?-10 aliphatic group, a saturated or unsaturated C3_8 cycloaliphatic group, which may optionally be at least monosubstituted, optionally containing at least one heteroatom as a ring member, which may be fused with a mono- or polycyclic ring system and / or may be linked via a linear C-10 alkylene group or bridge and / or it may be in the form of a bridge by a linear or branched C? _ al alkylene group, or an optionally at least monosubstituted 5 or 6-membered aryl or heteroaryl group, which may be fused with a mono- or polycyclic ring system and / or it can be linked via a linear or branched alkylene group C? _? 0, preferably Rx0 represents a linear or branched C? _10 alkyl group, a C5-6 cycloaliphatic group, which can be optionally be at least monosubstituted, optionally containing at least one heteroatom as a ring member, which may be fused with a mono- or polycyclic ring system and / or may be linked via a linear or bridged C 1 -C 3 alkylene group and / or it may be in the form of a bridge by a straight or branched C?-3 alkylene group, or an optionally at least monosubstituted 5 or 6-membered aryl or heteroaryl group, which may be fused with a mono- or polycyclic ring system and / or can be linked via a straight or branched C? _3 alkylene group, more preferably R 10 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group, an optionally at least monosubstituted phenyl group, a group optionally at least monosubstituted benzyl, an optionally at least monosubstituted naphthyl group, which may be linked via an alkylene group C 3 _3, an optionally at least monosubstituted thienyl group, a 2,1,3-Be group optionally at least monosubstituted nzothiadiazole, an optionally at least monosubstituted Benzo [b] thiophenyl group, an Imidazo [2. lb] thiazole optionally at least monosubstituted, an optionally at least monosubstituted lH-pyrazole group or a 7,7-Dimethyl-2-oxo-bicyclo- [2.2.1] -hept-1-yl group, more preferably still R10 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group, an optionally at least monosubstituted phenyl group, an optionally at least monosubstituted benzyl group, an optionally at least monosubstituted naphthyl group, which may be linked via a C ?_3 alkylene group / an optionally at least monosubstituted thienyl group, a group 2, 1, 3-Benzothiadiazole optionally at least monosubstituted, an optionally at least monosubstituted Benzo [b] thiophenyl group, an Imidazo group [2. lb] thiazole optionally at least monosubstituted, an optionally at least monosubstituted lH-pyrazole group or a 7,7-Dimethyl-2-oxo-bicyclo- [2.2.1] -hept-1-yl group, in which said substituents, if they are present, they are identical or different and are selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a formyl group, a phenyl group, a phenoxy group, a phenoxy group substituted by bromine at position 4 and a methylsulfonyl group, and R1-R9 and R ^ -R13 have the meaning indicated above, optionally in the form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemate or as a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any mixing ratio, or one of its corresponding N-oxides, one of its corresponding salts, or one of its corresponding solvates. Furthermore, the compounds of general formula I indicated above are preferred, in which R 11 represents a linear or branched, saturated or unsaturated, optionally at least monosubstituted C?-Α 0 aliphatic group, a saturated or unsaturated C 3-8 cycloaliphatic group, which may optionally be at least monosubstituted, optionally containing at least one heteroatom as a ring member, which may be fused with a mono- or polycyclic ring system and / or may be linked via a linear C-10 alkylene group or in the form of bridge and / or may be bridged by a linear or branched C? _ al alkylene group, or an optionally at least monosubstituted 5 or 6-membered aryl or heteroaryl group, which may be fused to a mono- or polycyclic ring system and / or it can be linked via a linear or branched alkylene group, preferably R 11 represents a linear or branched C 1-10 alkyl group, a C 5-6 cycloaliphatic group, saturated or unsaturated, which may optionally be at least monosubstituted, optionally containing at least one heteroatom as a ring member, which may be fused with a mono- or polycyclic ring system and / or may be linked via a linear C? _3 alkylene group or in the form of a bridge and / or may be in the form of a bridge by a linear or branched C? -3 alkylene group, or an optionally at least monosubstituted 5 or 6-membered aryl or heteroaryl group, which may be fused to a system ring mono- or polycyclic and / or can be linked via a straight or branched C? -3 alkylene group, more preferably R11 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group, a phenyl group optionally at least monosubstituted, an optionally at least monosubstituted benzyl group, an optionally at least monosubstituted naphthyl group, which may be linked via an alkylene group C ?_3, an optionally at least monosubstituted thienyl group is an optionally at least monosubstituted 2, 1, 3-benzothiadiazole group, an optionally at least monosubstituted Benzo [b] thiophenyl group, an Imidazo group [2. lb] thiazole optionally at least monosubstituted, an optionally at least monosubstituted IH-pyrazole group or a 7,7-Dimethyl-2-oxo-bicyclo- [2.2.1] -hept-1-yl group, more preferably still R11 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group, an optionally at least monosubstituted phenyl group, an optionally at least monosubstituted benzyl group, an optionally at least monosubstituted naphthyl group, which can be linked via an alkylene group C? _3, an optionally at least monosubstituted thienyl group, an optionally at least monosubstituted group 2, 1,3-Benzothiadiazole, an optionally at least monosubstituted Benzo [b] thiophenyl group, an Imidazo group [2. lb] thiazole optionally at least monosubstituted, an optionally at least monosubstituted IH-pyrazole group or a 7,7-Dimethyl-2-oxo-bicyclo- [2.2.1] -hept-1-yl group, in which said substituents, if they are present, they are identical or different and are selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a formyl group, a phenyl group, a phenoxy group, a phenoxy group substituted by bromine in the 4-position and a methylsulfonyl group, and the residues Rx-R10, R12 and R13 have the meaning indicated above optionally in the form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any mixture ratio, or one of its corresponding N-oxides, one of its corresponding salts, or one of its corresponding solvates. Also preferred are compounds of general formula I indicated above, in which R 12 represents a linear or branched, saturated or unsaturated, optionally at least monosubstituted C? _?? Aliphatic group, a saturated or unsaturated C3_8 cycloaliphatic group, which may be optionally at least monosubstituted, optionally containing at least one heteroatom as a ring member, which may be fused with a mono- or polycyclic ring system and / or may be linked via a linear C 1 -C 0 alkylene group or in the form of bridge and / or may be bridged by a linear or branched C? _ al alkylene group, or an optionally at least monosubstituted 5 or 6-membered aryl or heteroaryl group, which may be fused to a mono- or polycyclic ring system and / or it can be linked via a linear or branched C? _? al alkylene group, preferably R 12 represents a linear or branched C? _? 0 alkyl group, a C 5-6 cycloaliphatic group, tured or unsaturated, which may optionally be at least monosubstituted, optionally containing at least one heteroatom as a ring member, which may be fused with a mono- or polycyclic ring system and / or may be linked via an alkylene group C? _3 linear or bridged and / or may be in the form of a bridge by a linear or branched C? -3 alkylene group, or an optionally at least monosubstituted 5 or 6-membered aryl or heteroaryl group, which may be fused to a mono- or polycyclic ring system and / or can be linked via a linear or branched C? _3 alkylene group, more preferably R 12 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group, a phenyl group optionally at least monosubstituted, an optionally at least monosubstituted benzyl group, an optionally at least monosubstituted naphthyl group, which may be linked via an alkylene group C ?3, an optionally at least one thienyl group substituted, an optionally at least monosubstituted 2, 1, 3-benzothiadiazole group, an optionally at least monosubstituted Benzo [b] thiophenyl group, an Imidazo group [2. lb] thiazole optionally at least monosubstituted, an optionally at least monosubstituted lH-pyrazole group or a 7,7-Dimethyl-2-oxo-bicyclo- [2.2.1] -hept-1-yl group, more preferably still R12 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group, an optionally at least monosubstituted phenyl group, an optionally at least monosubstituted benzyl group, an optionally at least monosubstituted naphthyl group, which can be linked via an alkylene group C? _3, an optionally at least monosubstituted thienyl group, an optionally at least monosubstituted 2, 1, 3-benzothiadiazole group, an optionally at least monosubstituted Benzo [b] thiophenyl group, an Imidazo group [2. lb] thiazole optionally at least monosubstituted, an optionally at least monosubstituted lH-pyrazole group or a 7,7-Dimethyl-2-oxo-bicyclo- [2.2.1] -hept-1-yl group, in which said substituents, if they are present, they are identical or different and are selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a formyl group, a phenyl group, a phenoxy group, a phenoxy group substituted by bromine at position 4 and a methylsulfonyl group, and residues RAR11 and R13 have the meaning indicated above, optionally in the form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any mixing ratio, or one of its corresponding N-oxides, one of its corresponding salts, or one of its corresponding solvates. Also preferred are compounds of general formula I, in which R represents a linear or branched, saturated or unsaturated CX-10 aliphatic group, optionally at least monosubstituted, a saturated or unsaturated C3_8 cycloaliphatic group, which may optionally be at least monosubstituted , optionally containing at least one heteroatom as a ring member, which may be fused with a mono- or polycyclic ring system and / or may be linked via a linear or bridged C al _? al alkylene group and / or may be be bridged by a linear or branched C? -5 alkylene group, or an optionally at least monosubstituted 5 or 6 membered aryl or heteroaryl group, which may be fused with a mono- or polycyclic ring system and / or may be linking via a linear or branched C? _? al alkylene group, preferably R 13 represents a linear or branched C? _? alquilo alquilo grupo alkyl group, a C 5-6 cycloaliphatic, saturated or unsaturated group, which it may optionally be at least monosubstituted, optionally containing at least one heteroatom as ring member, which may be fused with a mono- or polycyclic ring system and / or may be linked via a straight or linear C?-3 alkylene group bridge and / or may be in the form of a bridge by a linear or branched C? -3 alkylene group, or an optionally at least monosubstituted 5 or 6-membered aryl or heteroaryl group, which may be fused with a mono- or polycyclic and / or can be linked via a linear or branched C1-3 alkylene group, more preferably R13 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group, an optionally at least monosubstituted phenyl group, an optionally at least monosubstituted benzyl group, an optionally at least monosubstituted naphthyl group, which may be linked via an alkylene group C3_3, an optionally at least monosubstituted thienyl group, a group 2.1, 3-Benzothiadiazole optionally at least monosubstituted, an optionally at least monosubstituted Benzo [b] thiophenyl group, an Imidazo group [2. lb] thiazole optionally at least monosubstituted, an optionally at least monosubstituted IH-pyrazole group or a 7,7-Dimethyl-2-oxo-bicyclo- [2.2.1] -hept-1-yl group, more preferably still R13 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group, an optionally at least monosubstituted phenyl group, an optionally at least monosubstituted benzyl group, an optionally at least monosubstituted naphthyl group, which can be linked via an alkylene group C? -3, an optionally at least monosubstituted thienyl group, an optionally at least monosubstituted group 2, 1,3-Benzothiadiazole, an optionally at least monosubstituted Benzo [b] thiophenyl group, an Imidazo [2.lb] thiazole group optionally at less monosubstituted, an optionally at least monosubstituted lH-pyrazole group or a 7,7-Dimethyl-2-oxo-bicyclo- [2.2.1] -hept-1-yl group, wherein said substituents, if present, are identical or different and are selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a formyl group, a phenyl group, a phenoxy group, a group phenoxy substituted by bromine in the 4-position and a methylsulfonyl group, and R1-R12 have the meaning indicated above optionally in the form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemate or in the form of a mixture of at least two of their stereoisomers, preferably enantiomers and / or diastereomers, in any mixing ratio, or one of its corresponding N-oxides, one of its corresponding salts, or one of its corresponding solvates. Particularly preferred are compounds of general formula I, wherein R1 represents a phenyl group, which is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C6-6alkyl, linear or branched C6-6 alkoxy, - (C = 0) -H, -OH, -CF3, -OCF3, -CN and -COOH, R2 represents a phenyl group, which is unsubstituted or substituted by 1, 2, 3 , 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, straight or branched C? _6 alkyl, linear or branched C? -6 alkoxy, - (C = 0) -H, -OH, -CF3, -OCF3, -CN and -COOH, R represents a branched, unsubstituted linear C6-6 alkyl group, R4 represents a hydrogen atom, -CN, -COOH, an unsubstituted linear or branched C6 alkyl group, or a phenyl group, wherein said phenyl is unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, or straight or branched C? -6 alkyl, C6-6 linear or branched alkoxy ficado, - (C = 0) -H, -OH, -CF3, -OCF3, -CN and -COOH, R5 represents a group -0-S02-R6, a group -NH-CO-R7, a group -NH2 , a group -NH-S02-R8, or a group -NR9-S02-R10 or a group -OC (= 0) -R11, R6 represents a phenyl ring, which is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C? -6 alkyl, linear or branched C? -6 alkoxy, - (C = 0) -H, -OH, -CF3, -0CF3, -CN and -COOH, R7 represents a linear or branched C? _5 alkyl group, wherein said C? -5 alkyl group is unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, -SH, linear or branched C6-6 alkoxy, -FC3 and -OCF3; a cyclopentyl or cyclohexyl group, wherein said cyclopentyl or cyclohexyl group is unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, -SH , linear or branched C_6 alkoxy, - CF3 and -0CF3; or a phenyl group, wherein said phenyl group is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, straight or branched C 1-6 alkyl, alkoxy Linear or branched C? -6, - (C = 0) -H, -OH, -CF3, -OCF3 / -CN and -COOH, R8 represents a linear or branched C? -5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1,3-benzothiodiazolyl, benzo [b] thiophenyl, benzo [b] furanyl, imidazo [2, lb] thiazolyl and pyrazolyl, wherein said aryl or heteroaryl group is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C? -6 alkyl, linear or branched C6-6 alkoxy, phenyl (optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, linear or branched C6-6 alkyl and linear or branched C6-6 alkoxy), phenoxy (optionally substituted with 1, 2, 3, 4 or 5 independently selected substituents from the group consisting of F, Cl, Br, -OH, linear C? _6 alkyl or branched and linear or branched C6-6 alkoxy), S02-CH3, (C = 0) -H, -OH, -CF3, -OCF3, -CN and -COOH and said aryl or heteroaryl group is optionally linked via an alkylene group Ci_3; Or a cyclohexyl group, in which said cyclohexyl group is optionally linked via a C? _3 alkylene group in the form of a bridge and / or is linked via a linear or branched C al-3 alguylene group in the form of a bridge and is unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, straight or branched C? _6 alkyl, linear or branched C? _6 alkoxy, - (C = 0) - H, -OH, -CF3 / = 0, -0CF3, -CN and -COOH; R9 represents a group -S02-R12; a group - (C = 0) -R13; a linear or branched C6-6 alkyl group; or a phenyl radical, wherein said phenyl radical is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C? _alkyl, linear or branched C6-6 alkoxy, - (C = 0) -H, -OH, -CF3, -0CF3, -CN and -COOH and / or said phenyl radical is linked via an alkylene group C3 -3 in the form of bridge; R10 represents a linear or branched C? -5 alkyl; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1,3-benzothiodiazolyl, benzo [b] thiophenyl, benzo [b] furanyl, imidazo [2, lb] thiazolyl and pyrazolyl, wherein said aryl or heteroaryl group is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C? -6 alkyl, linear or branched C6-6 alkoxy, phenyl (optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, linear or branched C? _6 alkyl and linear or branched C6-6 alkoxy), phenoxy (optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, linear C 1-6 alkyl or branched and linear or branched C6-alkoxy), S02-CH3, - (C = 0) -H, -OH, -CF3, -OCF3, -CN and -COOH and said aryl or heteroaryl group is optionally linked via a group to C, -C3; or a cyclohexyl group, wherein said cyclohexyl group is optionally linked via a C 1 -C 3 alkylene group in bridged form and / or is linked via a linear or branched C 1 -C 3 alkylene group in bridged form and is unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C? _6 alkyl, linear or branched C? -6 alkoxy, - (C = 0 ) -H, -OH, -CF3, = 0, -0CF3, -CN and -COOH; R11 represents a linear or branched C alqu _5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1,3-benzothio diazolyl, benzo [b] thiophenyl, benzo [b] furanyl, imidazo [2, lb] thiazolyl and pyrazolyl, wherein said aryl or heteroaryl group is unsubstituted or substituted by 1, 2 , 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C6-6 alkyl, straight or branched C6-6 alkoxy, phenyl (optionally substituted with 1, 2, 3 , 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, linear or branched C6-alkyl, and straight or branched C6-6 alkoxy), phenoxy (optionally substituted with 1, 2 or , 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, linear or branched C 1-6 alkyl and straight or branched C 1-6 alkoxy), S02-CH 3, - (C = 0) -H, -OH, -CF3, -OCF3, -CN and -COOH and said aryl or heteroaryl group is optionally linked via an alkylene group C? _3; or a cyclohexyl group, in which said cyclohexyl group is optionally linked via a C 1 -C 3 alkylene group in the bridged form and / or is linked via a CX_3 linear or branched aliphenylene group in bridged form and is unsubstituted or substituted , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C? _6 alkyl, linear or branched C? _6 alkoxy, - (C = 0) -H, -OH, -CF3, = 0, -OCF3, -CN and -COOH; R12 represents a linear or branched C alqu _5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1,3-benzothiodiazolyl, benzo [b] thiophenyl, benzo [b] furanyl, imidazo [2, lb] thiazolyl and pyrazolyl, wherein said aryl or heteroaryl group is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C? -6 alkyl, linear or branched C6-6 alkoxy, phenyl (optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, linear or branched C? _6 alkyl and straight or branched C6-alkoxy), phenoxy (optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, linear C? -6 alkyl or branched and linear or branched C6-alkoxy), S02 ~ CH3, (C = 0) -H, -OH, -CF3, -OCF3, -CN and -COOH and said aryl or heteroaryl group is optionally linked via a group alkylene C? _3; or a cyclohexyl group, wherein said cyclohexyl group is optionally linked via a C? _3 alkylene group in bridged form and / or is linked via a linear or branched C al__3 alkylene group in bridged form and is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, straight or branched C6-6 alkyl, straight or branched C6-6 alkoxy, - (C = 0) -H, -OH, -CF3, = 0, -0CF3, -CN and -COOH; R13 represents a linear or branched C alqu _5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1,3-benzothiodiazolyl, benzo [b] thiophenyl, benzo [b] furanyl, imidazo [2, lb] thiazolyl and pyrazolyl, wherein said aryl or heteroaryl group is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C? .6 alkyl, linear or branched C6-6 alkoxy, phenyl (optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, linear or branched C? _6 alkyl and linear or branched C6-alkoxy), phenoxy (optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, linear C 1 alkyl or branched and linear or branched C6-6 alkoxy), S02-CH3, - (C = 0) -H, -OH, -CF3, -0CF3, -CN and -COOH and said aryl or heteroaryl group is optionally linked via a group to L alkylene C? _3; or a cyclohexyl group, wherein said cyclohexyl group is optionally linked via a C? _3 alkylene group in bridged form and / or is linked via a straight or branched C? _3 alkylene group in the bridged form and is unsubstituted or substituted 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C? _6 alkyl, linear or branched C? _6 alkoxy, - (C = 0) -H , -OH, -CF3, = 0, -0CF3, -CN and -COOH; optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any mixture ratio, or one of its N-oxides corresponding, one of their corresponding salts, or one of their corresponding solvates, especially to compounds of the formula Ib, (Ib) in which X represents a halogen atom, preferably a chlorine atom, R5 represents a group -0-S02-R6, a group -NH-CO-R7, a group -NH2 / a group -NH-S02- R8, or a group -NR9-S02-R10 or a group -OC (= 0) -R11, R6 represents a phenyl ring, which is unsubstituted or substituted by 1, 2, 3, 4 or 5 independently selected substituents (s) ) of the group consisting of F, Cl, Br, linear or branched C? -6 alkyl, linear or branched C? -6 alkoxy, - (C = 0) -H, -OH, -CF3, -OCF3, -CN and -COOH, R7 represents a linear or branched C? -5 alkyl group, wherein said C? _5 alkyl group is unsubstituted or substituted by 1, 2, 3, 4 or 5 independently selected substituents of the group consisting of in F, Cl, Br, -OH, -SH, linear or branched C6. alkoxy, -FC3 and -OCF3; a cyclopentyl or cyclohexyl group, wherein said cyclopentyl or cyclohexyl group is unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, -SH , linear or branched C6. alkoxy, -FC3 and -OCF3; or a phenyl group, in which said phenyl group is unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C? -6 alkyl, linear or branched C6-alkoxy, - (C = 0) -H, -OH, -CF3, -OCF3, -CN and -COOH, R8 represents a linear or branched C? -5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1,3-benzothio diazolyl, benzo [b] thiophenyl, benzo [b] furanyl, imidazo [2, lb] thiazolyl and pyrazolyl, wherein said aryl or heteroaryl group is unsubstituted or substituted by 1, 2 , 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C 1-6 alkyl, linear or branched C 1-6 alkoxy, phenyl (optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, straight or branched C 1-6 alkyl, and straight or branched C 1-6 alkoxy), phenoxy (optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, straight or branched C 1-6 alkyl and straight or branched C 1-6 alkoxy), S02-CH 3, - (C = 0) -H, -OH, -CF3 / -OCF3, -CN and -COOH and said aryl or heteroaryl group is optionally linked via an alkylene group C? -3; or a cyclohexyl group, wherein said cyclohexyl group is optionally linked via a C? _3 alkylene group in bridged form and / or is linked via a linear or branched C? _3 alkylene group in bridged form and is unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, straight or branched alkyl, linear or branched C 1 - alkoxy, - (C = 0) -H , -OH, -CF3, = 0, -0CF3, -CN and -COOH; R9 represents a group -S02-R12; a group - (C = 0) -R13; a linear or branched Cx_6 alkyl group; or a phenyl radical, wherein said phenyl radical is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C? _6 alkyl, linear or branched C6-alkoxy, - (C = 0) -H, -OH, -CF3, -0CF3, -CN and -COOH and / or said phenyl radical is linked via an alkylene group C3_3 in the form of bridge; R10 represents a linear or branched C? _5 alkyl; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1,3-benzothiodiazolyl, benzo [b] thiophenyl, benzo [b] furanyl, imidazo [2, lb] thiazolyl and pyrazolyl, wherein said aryl or heteroaryl group is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C? _6 alkyl, alkoxy Linear or branched C, ~ 6, phenyl (optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, linear or branched C? -6 alkyl? and linear or branched C6-alkoxy), phenoxy (optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, straight or branched C6 alkyl and linear or branched C6-6 alkoxy), S02-CH3, - (C = 0) -H, -OH, -CF3, -OCF3, -CN and -COOH and said aryl or heteroaryl group is optionally linked via an alkyl group. uileno C? _3; or a cyclohexyl group, wherein said cyclohexyl group is optionally linked via a C? _3 alkylene group in bridged form and / or is linked via a linear or branched C al-3 alkyl group in bridged form and is unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C6-6 alkyl, linear or branched C6-6 alkoxy, - (C = 0) -H, -OH, -CF3, = 0, -0CF3, -CN and -COOH; R11 represents a linear or branched C? -5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1,3-benzothio diazolyl, benzo [b] thiophenyl, benzo [b] furanyl, imidazo [2, lb] thiazolyl and pyrazolyl, wherein said aryl or heteroaryl group is unsubstituted or substituted by 1, 2 , 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, straight or branched C 1-6 alkyl, linear or branched CX 6 alkoxy, phenyl (optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, straight or branched Cx_6 alkyl and straight or branched Cx_6 alkoxy), phenoxy (optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, linear or branched Cx_6 alkyl and linear or branched C6_6 alkoxy), S02-CH3, (C = 0) -H, -OH, -CF3, -0CF3, -CN and -COOH and said aryl or heteroaryl group is optionally linked via an alkylene group C3_3; or a cyclohexyl group, wherein said cyclohexyl group is optionally linked via a Cx_3 alkylene group in bridged form and / or is linked via a linear or branched C3_3 alkylene group in bridged form and is unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched CX-e alkyl, straight or branched Cx_6 alkoxy, - (C = 0) -H, -OH, -CF3 , = 0, -OCF3, -CN and -COOH; R12 represents a linear or branched Cx_5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1,3-benzothiodiazolyl, benzo [b] thiophenyl, benzo [b] furanyl, imidazo [2, lb] thiazolyl and pyrazolyl, wherein said aryl or heteroaryl group is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C? -6 alkyl, linear or branched Cx_6 alkoxy, phenyl (optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, linear or branched Cx-6 alkyl and Cx alkoxy ~ 6 linear or branched), phenoxy (optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, linear or branched Cx_6 alkyl and linear or branched Cx-6 alkoxy), S02-CH3, - (C = 0) -H , -OH, -CF3, -OCF3, -CN and -COOH and said aryl or heteroaryl group is optionally linked via an alkylene group C3_3; or a cyclohexyl group, wherein said cyclohexyl group is optionally linked via a Cx_3 alkylene group in bridged form and / or is linked via a linear or branched C _ 3 alguylene group in bridged form and is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cx-6 alkyl, linear or branched C alco _ alkoxy, - (C = 0) -H, - OH, -CF3, = 0, -0CF3, -CN and -COOH; R13 represents a linear or branched C alqu _5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1,3-benzothiodiazolyl, benzo [b] thiophenyl, benzo [b] furanyl, imidazo [2, lb] thiazolyl and pyrazolyl, wherein said aryl or heteroaryl group is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cx_6 alkyl, linear Cx_6 alkoxy or branched, phenyl (optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, linear or branched C? -6 alkyl, and C? _6 alkoxy linear or branched), phenoxy (optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, linear or branched C? -6 alkyl, and C-alkoxy ? -6 linear or branched), S02-CH3, (C = 0) -H, -OH, -CF3, -OCF3, -CN and -COOH and said aryl or heteroaryl group is optionally linked via a group to the C? _3; or a cyclohexyl group, in which said cyclohexyl group is optionally linked via a C 1 -C 3 alkylene group in bridging form and / or is linked via a linear or branched C 1 -C 3 alkylene group in bridged form and is unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, straight or branched C? _6 alkyl, linear or branched C? _6 alkoxy, - (C = 0) - H, -OH, -CF3, = 0, -0CF3, -CN and -COOH; optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any mixture ratio, or one of its N-oxides corresponding ones, one of its corresponding salts, or one of its corresponding solvates. Particularly preferred are compounds of the general formula (I), (I) wherein R1 represents a phenyl group, which is monosubstituted by a halogen atom, preferably a chlorine atom, at the 4-position of the phenyl ring, R2 represents a phenyl group, which is monosubstituted by a halogen atom, preferably a chlorine atom, at the 4-position of the phenyl ring, R3 represents a linear or branched, unsubstituted Cx_6 alkyl group, preferably a methyl group, R4 represents a hydrogen atom, R5 represents a group -0-S02-R6, a group -NH-CO-R7, a group -? H2, a group -? H-S02-R8, or a group -? R9- S02-R10 R6 represents a phenyl ring, which is optionally substituted by one or more halogen atoms, preferably one or more fluorine atoms and / or one or more chlorine atoms, R7 represents a linear or branched Cx-.5 alkyl group , a linear or branched C? -5 alkyl group, which is at least partially fluorinated, a C3-8 cycloalkyl group, or a phenyl group, which is optionally substituted by one or more halogen atoms, preferably one or more fluorine atoms , R8 represents a linear or branched Cx-5 alkyl group, a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a fluorine atom, a chlorine atom, an unsubstituted phenyl group , a formyl group, a methylsulfonyl group, a benzyl group and a phenoxy group, which e is optionally monosubstituted by a bromine atom in its 4-position, a naphthyl group, which can be linked via a methylene or ethylene group, a Benzo [b] thiophene group, which is optionally substituted by one or more methyl groups and / or one or more chlorine atoms, a pyrazole group, which is optionally substituted by one or more substituents independently selected from the group consisting of a methyl group, an ethyl group and a phenyl group, an imidazo [2, lb] thiazole group, which is optionally substituted by one or more chlorine atoms, a thienyl group, a furyl group, a 2,1,3-benzothiadiazole group, a 7,7-dimethyl-2-oxo-bicyclo- group [2.2.1] - hept-1-yl, or a benzyl group, R9 represents a Cx_5 alkyl group, preferably a methyl group, a phenyl group, which is optionally substituted by one or more fluorine atoms and / or one or more chlorine atoms, a group benzyl, in which the ring is optionally substituted by one or more atoms of fluorine and / or one or more chlorine atoms, or a group -S02-R12, R10 represents a phenyl group, which is optionally substituted by one or more fluorine atoms and / or one or more chlorine atoms, R12 represents a Cx_5 alkyl group, preferably a methyl group, or a phenyl group, which is optionally substituted by one or more fluorine atoms and / or one or more chlorine atoms, optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any mixing ratio, or one of its corresponding N-oxides, one of its corresponding salts, or one of its corresponding solvates. Very particularly preferred are the substituted azetidine compounds of the general formula I indicated above, selected from the group consisting of [1] Ester of 4-fluorobenzenesulfonic acid 1- [bis- (4-chloro-phenyl) -methyl] -stransferonic acid 2-methyl-3-azetidinol, [2] N-. { (2S, 3R) -1- [Bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} -2,2,2-trifluoroacetamide, [3] (2S, 3R) -1- [Bis- (4-chloro-phenyl) -methyl] -2-methyl-3-azetidinamine, [4] Amide of acid . { l- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} hexanoic, [5] N-. { (2S, 3R) -1- [Bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} -4-fluoro-benzenesulfonamide, [6] Amide of acid. { (2S, 3R) -1- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} 2-thiophene sulfonic acid [7] Amide acid. { (2S, 3R) -1- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} cyclohexanecarboxylic, [8] Amide of acid. { (2S, 3R) -1- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} butan-1-sulfonic, [9] N-. { (2S, 3R) -1- [Bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} -3,5-difluoro-benzamide, [10] Amide. { trans-1- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} of naphthalene-2-sulfonic acid, [11] Amide. { trans-1- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} of biphenyl-4-sulfonic acid, [12] 4-Acetyl-N-. { trans-l- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} -benzenesulfonamide, [13] N-. { trans-1- [Bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} -4- (-bromo-phenoxy) -benzenesulfonamide, [14] N-. { trans-l- [Bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} -4-methylsulfonyl-benzenesulfonamide, [15] Amide. { trans-1- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} of 2,1,3-benzothiadiazole-4-sulfonic acid, [16] Amide. { trans-1- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} of 5-chloro-3-methyl-benzo [b] thiophene-2-sulfonic acid, [17] Amide. { trans-1- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} of 6-chloro-imidazo [2, 1-b] thiazole-5-sulfonic acid, [18] N-. { trans-1- [Bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} -3,5-dichloro-benzenesulfonamide, [19] Amide. { trans-1- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} of 2-naphthalene-1-yl-ethanesulfonic acid, [20] N-. { trans-1- [Bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} phenyl-methylsulfonamide, [21] N-. { trans-1- [Bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} - (7,7-dimethyl-2-oxo-bicyclo [2.2.1] hept-1-yl) -methylsulfonamide, [22] Amide. { trans-1- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} of naphthalene-1-sulfonic acid, [23] N-. { trans-1- [Bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} -4-phenoxy-benzenesulfonamide, [24] Amide. { trans-1- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} of 1,3,5-trimethyl-lH-pyrazol-4-sulfonic acid, [25] Amide. { trans-1- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} of benzo [b] thiophene-3-sulfonic acid, [26] Amide. { trans-1- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} of 5-methyl-1-phenyl-1H-pyrazole-4-suifonic acid, [27] N-. { trans-1- [Bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} -N-methyl-4-fluoro-benzenesulfonamide, [28] N-. { trans-l ~ [Bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} -N- (4-fluoro-benzyl) -4-fluoro-benzenesulfonamide, [29] N-. { trans-l- [Bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} -N-propyl-4-fluorobenzenesulfonamide, [30] N-. { trans-1- [Bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} -N- (methylsulfonyl) -4-fluorobenzenesulfonamide, [31] N-. { trans-1- [Bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} -N-bis (4-fluorobenzenesulfonamide), [32] N-. { (trans-1- [Bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl.} -4-fluorobenzenesulfonamide, and [33] N-. {(2R, 3S) -1- [Bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl.} -4-fluorobenzenesulfonamide; optionally in the form of an N-oxide, a corresponding salt or a corresponding solvate. Another aspect of the present invention consists in a process for the preparation of substituted azetidine compounds of general formula I indicated above and their corresponding stereoisomers, according to which at least one compound of general formula II, II wherein R1 to R4 have the meaning indicated above, reacts with at least one compound of the general formula X ^ SOa-R6 or X2-CO-Rx1, in which R6 and R11 have the meaning indicated above and X1 and X2 represent groups suitable projections, in a suitable reaction medium, optionally in the presence of at least one base, to obtain at least one compound of general formula I indicated above, in which R5 represents a group -0-S02 ~ Rd or a group -O -CO-R11, and optionally purifying and / or optionally isolating said compound (s), and optionally at least one of the compounds mentioned above, wherein R5 represents a group -0-S02-R6 or a group - O-CO-R11, reacts with ammonia, to obtain a compound of general formula I, in which R5 represents a group -NH2, and optionally purifying and / or optionally isolating said compound (s), and optionally at least one of the compounds mentioned above, in which R5 repress a group -NH2, reacts with at least one compound of general formula X3-COR7, X4-S02-R8 or X5-S02-R10, in which R7, R8 and R10 have the meaning indicated above and X3, X4 and X5 are suitable leaving groups, in a reaction medium, optionally in the presence of at least one base, to obtain a compound of general formula I indicated above, in which R 5 represents a group -NH-CO-R 7, a group -NH- S02-R8 or a group -NR9-S02-R10 with R9 representing a hydrogen atom, and optionally purifying and / or optionally isolating said compound (s), and optionally at least one compound of general formula I, in the which R5 represents a group -NR9-SO2-Rx0 with Rs representing a hydrogen atom, reacts with at least one compound of general formula X6-R9, in which R9 has the meaning indicated above except for one hydrogen atom and X6 is a leaving group, to obtain at least one compound of general formula I indicated above wherein R5 represents a group -NR9-S02-R10, and optionally purifying and / or optionally isolating said compound (s), or, according to which at least one compound of general formula III, III wherein R4 represents a hydrogen atom and Rx-R3 have the meaning indicated above, is oxidized to obtain at least one compound of general formula IV, IV in which R2-R3 have the meaning indicated above, which is optionally purified and / or optionally isolated, and reacts with at least one compound of general formula R5aH, in which R5a represents a group -NH2 or a group -NHR9, wherein R9 has the meaning indicated above, the resulting compound is optionally purified and / or optionally isolated and optionally reacts with at least one compound of general formula X3-CO-R7, X-S02-R8 or X5-SO2-Rx0, wherein R7, R8 and R10 have the meaning indicated above and X3, X4 and X5 represent a leaving group, in a reaction medium, optionally in the presence of at least one base, to obtain a compound of general formula I indicated above, wherein R5 represents a group -NH2, a group -? H-CO-R7, a group -? H-S02-R8, or a group -? R9-S02-R10, which is optionally purified and / or isolated. Said inventive process is also illustrated in the following chart 1: Scheme 1: with R5 = NR9-SO2-R10 R9? H Preferably step (a) of scheme 1 is carried out in one or more organic solvents as a reaction medium. Suitable solvents include, but are not limited to, halogenated, preferably chlorinated, organic solvents such as dichloromethane or chloroform and linear or cyclic ethers, such as tetrahydrofuran, 1,4-dioxane, or 1,1-dimethoxyethane. The reaction temperature as well as the duration of the reaction can vary widely. The optimum reaction temperature and the duration of a given reaction can be determined by conventional methods known in the art. Preferred reaction temperatures are 0-30 ° C, preferably 15-25 ° C. Suitable reaction times may vary from about 10 minutes to 3 days. Bases suitable for use in step (a) include organic bases such as triethylamine or pyridine as well as inorganic bases such as sodium hydroxide or potassium hydroxide. Mixtures of one or more organic bases and / or one or more inorganic bases can also be used. The leaving groups X1 and X2 can be of any type known in the art for this type of reaction. Preferably the leaving group is a halogen atom, more preferably a chlorine or bromine atom. Suitable reaction media for the reaction with ammonia according to step (b) of scheme 1 include, for example, alcohols such as methanol, ethanol, isopropanol or mixtures of at least two of these alcohols. The ammonia is preferably added as a concentrated, preferably aqueous, solution. The reaction temperature, the pressure as well as the duration of the reaction can vary widely. The optimum conditions can be determined by conventional methods known in the art. Preferred reaction temperatures range from room temperature, i.e., about 15-25 ° C, to the boiling point of the reaction medium. Suitable reaction times may vary, for example from about 10 minutes to 3 days. Obviously, the reaction can also be carried out in a reactor at elevated temperatures and pressure. In step (b), compounds of general formula I are preferably used, in which R 5 represents a group -0-S02-R 6 with R 6 representing a methyl group. The reaction steps (c) and (d) of the enzyme 1 can also be carried out under conventional conditions known to those skilled in the art. A suitable reaction medium used in these reaction steps preferably comprises one or more organic solvents. Suitable solvents include, but are not limited to, halogenated, preferably chlorinated, organic solvents such as dichloromethane or chloroform and linear or cyclic ethers, such as tetrahydrofuran, 1,4-dioxane, or 1,1-dimethoxyethane. The reaction temperature as well as the duration of the reaction can vary widely. Optimal conditions for a given reaction can be determined by conventional methods known to those skilled in the art. Preferred reaction temperatures are 0-30 ° C, preferably 15-25 ° C. The appropriate reaction times vary, e.g. from about 10 minutes to 3 days. Suitable bases that may be present during reaction steps (c) and (d) include organic bases such as triethylamine or pyridine as well as inorganic bases such as sodium hydroxide or potassium hydroxide. Mixtures of one or more organic bases and / or one or more inorganic bases can also be used. The leaving groups X3, X4, X5 and X6 can be of any type known in the art for this type of reaction. Preferably the leaving group is a halogen atom, more preferably a chlorine or bromine atom. The preparation of compounds of general formula IV according to step (e) of scheme 1 can preferably be carried out according to the literature of Katritzky et al., J. Heterocycl. Chem., 1994, 271-275; P.R.

Dave et al., J. Org. Chem., 1996, 61 (16), 5453, Synlett. 1991, (11), 783-784 and Axenrod et al., Tetrahedron Lett., 1993, 6677-6680. The respective bibliographic descriptions are incorporated by reference and are part of this description. The respective compounds of general formula R5aH, in which R5a represents a residue -NH2 or a group -NHR9, in which R9 has the meaning indicated above, are commercially available or can be prepared according to standard methods known to those skilled in the art. . Preferably, step (f) of scheme 1 is carried out in one or more organic solvents as a reaction medium, such as chlorinated organic solvents such as dichloromethane or chloroform, and preferably in the presence of sodium triacetoxyborohydride and acetic acid, or in the presence of H2 and an alcohol such as methanol and / or ethanol as a reaction medium. The reaction temperature as well as the duration of the reaction can vary widely. The optimum reaction temperature and the duration of a given reaction can be determined by conventional methods known to those skilled in the art. Preferred reaction temperatures are 0-30 ° C, preferably 15-25 ° C.

The substituted 3-azetidinol compounds of general formula III can be prepared according to Scheme 2 presented below: Scheme 2: In Scheme 2 the substituents Rx-R4 have the meaning indicated above and X represents a halogen atom, preferably a bromine or chlorine atom. The substituted hydroxy-alkenylene compounds used as starting material for reaction steps A and Al according to Scheme 2 are commercially available and / or can be prepared by conventional methods known to those skilled in the art, e.g. by reduction of the corresponding carbonyl compound with a suitable reducing agent such as lithium aluminum hydride, sodium borohydride or catalytic hydrogenation as described, for example, in Catalysis Letters, 1999, 62 (2-4), 175-177; Tetrahedron, 1984, 40 (7), 1195-1198; J. Org. Chem., 1999, 64 (7), 2582-2589; J. A. Chem. Soc., 2001, 12168-12175; Synlett. 1763-65 (1999); Bull. Soc. Chim. France, 132 (5-6), 522-30 (nineteen ninety five); Tetrahedron Lett. , 43 (49), pages 8893-8896 (2002) and J. Natural Products, 65 (6), 902-908 (2002). The respective bibliographic descriptions are incorporated as a reference and are part of this disclosure. The halogenated alkenylene compounds used as starting material for reaction steps B and Bl are commercially available and / or can be prepared from the corresponding hydroxy-alkenylene compounds using a suitable halogenating agent such as thionyl chloride, triphenyl phosphin / carbontetrachloride, bromine, hydrobromic acid, triphenyl phosphin / carbontetrabromide, phosphoric tribromide and others described in the literature, for example, in Chem. Ber. 123 (12), 2387-94, 1990; J. Am. Chem. Soc., 111 (9), 3363-3368, 1989; J. Org. Chem., 63 (25), 9565-68, 1998; Heterocycles 32 (5), 965-73, 1991; Drug, 44 (12), 1167-91, 1989; Synthesis, 8, 598-603, 1989; and J. Med. Chem., 33 (3), 908-18, 1990. The respective literature descriptions are incorporated by reference and are part of this description. Reaction steps A, B and Bl can be performed according to the description of Higgins et al., J. Heterocyclic Chem., 1971, 8, 1059-1062 and in US 5,073,646. The respective bibliographic descriptions are incorporated as a reference and are part of this disclosure. The reaction step A is preferably carried out in an organic solvent such as dichloromethane, chloroform, carbontetrachloride or corresponding mixtures as reaction medium. The reaction temperature as well as the duration of the reaction can vary widely. Optimal conditions for a given reaction can be determined by conventional methods known to those skilled in the art. Preferred reaction temperatures are -10 ° C to +30 ° C, preferably from 0 ° C to 25 ° C, more preferably from 0 ° C to 10 ° C. Suitable reaction times vary from a few minutes to several hours, preferably from 3 to 8 hours. Reaction step B is preferably carried out by dissolving the compound in a suitable reaction medium, preferably a linear ether such as diethyl ether, or a cyclic ether, such as tetrahydrofuran, 1,4-dioxane or 1,1-dimethoxyethane, and in the presence of an aqueous solution of a base, preferably selected from the group consisting of an alkali metal such as lithium, sodium or potassium, stirring vigorously. The reaction temperature as well as the duration of the reaction can vary widely. The optimal reaction conditions for a given reaction can be determined by conventional methods known in the art. Preferred reaction temperatures range from 10 ° C to the boiling point of the reaction mixture, preferably from 15 ° C to 25 ° C. Suitable reaction times vary from a few minutes to several hours, preferably from 3 to 8 hours. The reaction step Bl is preferably carried out in the presence of an oxidizing agent such as peracetic acid, m-chloro perbenzoic acid, N-Bromsuccinimide or the like.

The 3-azetidinol compound is obtained by carrying out the reaction step (c) according to the methods described in the M.E. Jung, J. Org. Chem., 1991, 56 (24), 6729-6730; V.R. Gaertner, J. Org. Chem., 1967, 32, 2972, Katrizky et al., J. Heterocycl. Chem. 1994, 271-275, P.R. Dave et al, J. Org. Chem., 1996, 61 (16), 5453 and US 5,073,646. The respective bibliographic descriptions are incorporated by reference and are part of this description.

The corresponding amines of general formula C (H) (R1) (R2) -NH2 are commercially available and / or can be obtained according to Scheme 3 presented below: Scheme 3: The reaction steps A2, B2, C2a and C2b can be carried out by conventional methods known in the art. Step A2 is for example described in Hajipour et al., Synth. Commun. 1999, 29 (10), 1697-1701, A.

Sasse et al., Arch. Pharm., 2001, 334 (2), 45-52. Step B2 is for example described in the publication by Fernandez et al., Synthesis 2001, (2), 239-242; Baruah et al., Synlett, 1999, (4), 409-410. Steps C2a and C2b are, for example, described in the publications of M. Grisar et al., J. Med. Chem., 1973, 885 or Dejaegher et al., Synlett. 2002, 113-115. The respective bibliographic descriptions are incorporated by reference and are part of this description. Another aspect of the present invention is a process for the preparation of substituted azetidine compounds of general formula I indicated above and their corresponding stereoisomers, according to which at least one compound of general formula V v in which R1 and R2 have the meaning indicated above and Y represents a halogen atom, preferably a chlorine atom or a bromine atom, reacts with at least one compound of general formula VI, SAW optionally in the form of a salt, in which R3, R4 and R5 have the meaning indicated above, in a suitable reaction medium, optionally in the presence of a base, and the resultant azetidine compound (s) ( s) is / are optionally purified (s) and / or optionally isolated (s). The compounds of general formula V can be obtained by conventional methods known to those skilled in the art. Some examples of methods are illustrated in Scheme 4 presented below: Scheme 4: The compounds of general formula (Va) can, for example, be obtained according to step A3 of scheme 4 by reduction of a ketone compound with a suitable reducing agent such as sodium borohydride in a suitable reaction medium such as alcohol, preferably methanol, in which the reaction temperature is preferably maintained in the range of 0 ° C and the boiling point of the reaction medium. The compounds of the general formula (Va) can, for example, also be obtained according to step B3 of scheme 4 by reaction of Grignard in a suitable inert reaction medium such as diethyl ether or tetrahydrofuran, in which the reaction temperature is preferably maintained in the range of 0 ° C and the boiling point of the reaction medium. The corresponding starting materials for the reactions according to steps A3 and B3 of scheme 4 are commercially available and / or can be prepared by conventional methods known to those skilled in the art. The reaction step C3 of scheme 4, wherein X represents a halogen atom, preferably a chlorine or bromine atom, can be carried out using a suitable halogenating agent such as hydrobromic acid, thionyl bromide, thionyl chloride, acetyl bromide, in a suitable reaction such as acetic acid, benzene, toluene, dichloromethane or chloroform, in which the reaction temperature is preferably maintained in the range of 0 ° C to the boiling point of the reaction medium. The reaction of at least one compound of general formula V indicated above with at least one compound of general formula VI can preferably be carried out in an inert reaction medium., in which acetonitrile, tetrahydrofuran or corresponding mixtures are preferred. Suitable bases include organic bases such as triethylamine and inorganic bases such as alkali metal carbonates, preferably potassium carbonate, or potassium iodide. The reaction temperature is preferably in the range of room temperature to the boiling point of the reaction medium. Reaction times can vary widely. The compounds of general formula VI can be prepared from the corresponding benzohydrilazetidine compounds of general formula VII, VII by hydrogenolysis, preferably in the presence of palladium metal on carbon, in a reaction medium such as an alcohol such as methanol. Preferably said hydrogenolysis is carried out at room temperature, that is, at about 15-25 ° C. Once the hydrogenolysis is complete, the compounds of general formula VI are preferably isolated in the form of a corresponding salt as hydrochloride or hydrobromide.

The compounds of general formula VII can be prepared according to the methods described, for example, in US Pat. No. 5,073,646 and J. Frigola, J. Med. Chem., 1993, 36, 801-810. The compounds of general formula VI are usually obtained in the form of a mixture of diastereoisomers. The respective enantiomers can be obtained by resolution of the racemate with HPLC by chiral columns or by crystallization with chiral derivatives obtained from the reaction of the corresponding racemate with chiral agents, as described in the publication of J. Frigola, J. Med. Chem. 1994, 37, 4195-4210 and J. Frigola, J. Med. Chem., 1995, 38, 1203-1215. The corresponding enantiomers can also be obtained by asymmetric epoxidation in a corresponding reaction as described in Scheme 2, which is carried out according to the method described in the publication of Sharpless et al., J. Am. Chem. Soc., 1980, 102, 5974-5976; J.A. Marshall et al., Org. Lett., 2000 2 (18), 2897-2900 using tert. -But hydroperoxide in the presence of titanium isopropoxide and diethyl or diisopropyl tartrate as an oxidant. The respective bibliographic descriptions are incorporated by reference and are part of this description.

During the processes described above it may be necessary and / or desirable to protect sensitive groups or reagents. The introduction of conventional protecting groups as well as their removal can be effected by methods known to those skilled in the art. If the same substituted azetidine compounds of general formula (I) and / or (Ib) are obtained in the form of a mixture of stereoisomers, particularly enantiomers or diastereomers, said mixtures can be separated by conventional methods known in the art, for example . chromatographic methods or fractional crystallization with chiral agents. It is also possible to obtain pure stereoisomers via stereoselective synthesis. Substituted azetidine compounds of general formula I and / or (Ib), which comprise saturated, unsaturated or aromatic rings containing nitrogen atoms, may also be obtained in the form of their N-oxides by conventional methods known to those skilled in the art. Another aspect of the present invention consists in a process for the preparation of salts of substituted azetidine compounds of general formula (I) and / or (Ib), their stereoisomers or their N-oxides, in which at least one compound of the general formula (I) and / or (Ib) having at least one basic group reacts with at least one mineral and / or organic acid, preferably in the presence of a suitable reaction medium. Suitable reaction media are, for example, any of those indicated above. Suitable mineral acids are hydrochloric, hydrobromic, phosphoric, sulfuric, nitric acids; suitable organic acids are citric, maleic, fumaric, tartaric or their derivatives, p-toluenesulfonic, methanesulfonic or camphorsulfonic acids. Another aspect of the present invention also consists in a process for the preparation of salts of substituted azetidine compounds of general formula (I) and / or (Ib), their stereoisomers or their N-oxides, in which at least one compound of formula General (I) and / or (Ib) having at least one acid group reacts with at least one or more suitable bases, preferably in the presence of a suitable reaction medium. Suitable bases are eg. hydroxides, carbonates or alkoxides, including suitable cations, derivatives eg. of alkali metals, alkaline earth metals or organic cations, for ex. [NHnR4-r + in which n is O, 1, 2, 3 or 4 and R represents a linear or branched Cx-4 alkyl radical. Suitable reaction media are, for example, any of those indicated above. The solvates, preferably hydrates, of the substituted azetidine compounds of general formula (I) and / or (Ib), of the corresponding stereoisomers, of their corresponding N-oxides, or of their corresponding salts can also be obtained by conventional methods known to the specialists in the technique. The purification and isolation of the substituted azetidine compounds of general formula (I) and / or (Ib) object of the present invention, or of a corresponding stereoisomer, or salt, or solvate or any of its intermediates can, if necessary, performed by conventional methods known to those skilled in the art, e.g. chromatographic methods or recrystallization. The substituted azetidine compounds of general formula (I) and / or (Ib), their N-oxides, their stereoisomers, their corresponding salts and solvates are toxicologically acceptable and therefore suitable as active pharmaceutical ingredients for the preparation of medicaments. Surprisingly, it has been observed that the substituted compounds of general formula I and / or (Ib) indicated above, their stereoisomers, their N-oxides, their corresponding salts and solvates have a high affinity for cannabinoid receptors, particularly cannabinoid receptors 1 ( CBX), that is, they act as antagonists on these receptors. Thus, another aspect of the present invention is a medicament comprising at least one substituted azetidine compound of general formula I indicated above including the compounds not claimed above, optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any mixture ratio, or one of its corresponding N-oxides, one of its corresponding salts, or one of its corresponding solvates, and optionally one or more pharmaceutically acceptable excipients. Said medicament may comprise any combination of one or more of the substituted azetidine compounds of general formula I and / or (Ib) indicated above, their stereoisomers, their N-oxides, their physiologically acceptable salts or their physiologically acceptable solvates. Preferably said medicament is suitable for the modulation (regulation) of cannabinoid receptors, preferably cannabinoid receptors 1 (CB), for the prophylaxis and / or treatment of disorders of the central nervous system, disorders of the immune system, disorders of the cardiovascular system, disorders of the endocrine system, disorders of the respiratory system, gastrointestinal tract disorders or disorders of reproduction.

More preferably, said medicament is suitable for the prophylaxis and / or treatment of one or more disorders selected from the group consisting of psychosis, schizophrenia, anxiety, depression, epilepsy, neurodegenerative disorders, cerebellar disorders, spinocerebellar disorders, cognitive disorders, cranial trauma, panic attacks, peripheral neuropathy, inflammation, glaucoma, migraine, Morbus Parkinson, Morbus Huntington, Morbus Alzheimer, Raynaud's disease, tremors, compulsive disorders, senile dementia, thymic disorders, late oral dyskinesia, bipolar disorders, cancer, induced movement disorders due to medications, dystonia, endotoxemic shock, hemorrhagic shock, hypotension, insomnia, immunological disorders, sclerotic plaques, vomiting, diarrhea, asthma, alimentary dysfunctions, preferably bulimia, anorexia, cachexia, obesity, type II diabetes mellitus (non-insulin-induced diabetes mellitus) dependent), disorders of the memo ria, pruritus, alcoholism, drug addiction, drug addiction, preferably abuse of one or more of the drugs selected from the group consisting of opioids, barbiturates, cannabis, cocaine, amphetamines, phencyclidine, hallucinogens and benzodiazepines, pain, or to potentiate the effect analgesic of narcotic and non-narcotic analgesics, or to influence intestinal transit. Preferably, in particular, the medicament of the present invention is suitable for the prophylaxis and / or treatment of pain, dysfunctions in food intake, preferably bulimia, anorexia, cachexia, obesity or type II diabetes mellitus (diabetes mellitus). non-insulin-dependent), preferably diabetes, psychosis, alcoholism, drug addiction and / or drug addiction, preferably drug addiction, diarrhea and / or pruritus. More preferably still, the medicament of the present invention is suitable for the prophylaxis and / or treatment of one or more disorders selected from the group consisting of obesity, psychosis and / or drug addiction. Another aspect of the present invention is the use of at least one substituted azetidine compound of general formula I and / or (Ib), including the above-mentioned non-claimed compounds, optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any mixture ratio, or one of its corresponding N-oxides, one of its corresponding salts, or one of its corresponding solvates, and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the modulation of cannabinoid receptors, preferably cannabinoid receptors 1 (CBX), for the prophylaxis and / or treatment of disorders of the central nervous system, disorders of the immune system, disorders of the cardiovascular system, disorders of the endocrine system, respiratory system disorders orio, gastrointestinal tract disorders or reproductive disorders. Particularly preferred is the use of at least one substituted azetidine compound of general formula I, including the above unclaimed compounds, optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any mixture ratio, or one of its corresponding N-oxides, one of its corresponding salts, or one of its corresponding solvates, and optionally one or more pharmaceutically acceptable excipients, for preparation of a medicament for the prophylaxis and / or treatment of one or more disorders selected from the group consisting of psychosis, schizophrenia, anxiety, depression, epilepsy, neurodegenerative disorders, cerebellar disorders, spinocerebellar disorders, cognitive disorders, cranial trauma, panic attacks, peripheral neuropathy, glaucoma, migraine, Morbus Parkinson, Morbus Huntington, Alzheimer's Morbus, Raynaud's disease, tremors, compulsive disorders, senile dementia, thymic disorders, tardive oral dyskinesia, bipolar disorders, cancer , movement disorders induced by drugs, dystonia, endotoxemic shock, hemorrhagic shock, hypotension, insomnia, immunological disorders, sclerotic plaques, vomiting, diarrhea, asthma, alimentary dysfunctions, preferably for the regulation of appetite, for maintenance, increase or reduction of body weight, bulimia, anorexia, cachexia, obesity, diabetes mellitus type II (non-insulin-dependent diabetes mellitus), memory disorders, alcoholism, pruritus, drug addiction, drug addiction, preferably abuse of one or more of the selected drugs of the group consisting of opioids, barbites, cannabis, cocaine, amphetamines, phencyclidine, hallucinogens and benzodiazepines, pain, or for the potentiation of the analgesic effect of narcotic and non-narcotic analgesics, or to influence intestinal transit. The medicament according to the present invention can be in any form suitable for application in humans and / or animals, preferably humans including newborns, children and adults and can be obtained by conventional methods known in the art. The composition of the medicine may vary according to the route of administration. The medicament of the present invention may for example be administered parenterally in combination with conventional liquid injectable excipients, such as water or suitable alcohols. Conventional pharmaceutical excipients for injection, such as stabilizers, solubilizers and buffers, may be included in these injectable compositions. These drugs are preferably injected intramuscularly, intraperitoneally or intravenously. The medicaments according to the present invention can also be formulated in compositions for oral administration containing one or more physiologically compatible excipients, in solid or liquid form. These compositions may contain conventional ingredients such as binders, fillers, lubricants and acceptable humectants. The compositions can take any convenient form, such as tablets, pellets, capsules, pills, aqueous or oily solutions, suspensions, emulsions or dry powder for reconstitution with water or other suitable liquid medium before use, for immediate or controlled release.

The liquid oral forms for administration may also contain certain additives such as sweeteners, flavors, preservatives and emulsifiers. Nonaqueous liquid compositions for oral administration, containing edible oils, can also be formulated. These liquid compositions can be conveniently encapsulated, for example in gelatin capsules for unit dosage. The compositions of the present invention can also be administered topically or by suppository. The daily dosage in humans and animals can vary according to factors based on the respective species or other factors such as age, sex, weight, degree of disease, etc. The daily dosage in humans can preferably be in the range of 1 to 2000, preferably 1 to 1500, more preferably even 1 to 1000 milligrams as the active principle to be administered in one or more doses per day. Pharmacological methods I. In-vitro determination of affinity for CB1 / CB2 receptors The in-vitro determination of the affinity of the substituted azetidine compounds of the present invention for CBX / CB2 receptors was carried out as described by Ruth's publication A. Ross, Heather C. Brockie et al., "Agonist-inverse agonist characterization at CBX and CB2 cannabinoid receptors of L-759633, L759656 and AM630", British Journal of Pharmacology, 126, 665-672, (1999). The respective parts of the bibliographic descriptions are incorporated by reference and are part of this description. The transfected human CBX and CB2 receptors have been obtained from Receptor Biology, Inc. The radioligand used with both receptors is [3H] -CP55940. II. In-vivo bioassay system for the determination of cannabinoid activity Model of tetrada in mouse Substances with affinity for cannabinoid receptors are known to produce a wide range of pharmacological effects. It is also known that intravenous administration of a substance with affinity for cannabinoid receptors in mice produces analgesia, hypothermia, sedation and catalepsy. Individually, none of these effects can be considered as proof that a tested substance has an affinity for cannabinoid receptors, since all of these effects are common to several classes of agents with central activity. However, the substances that show all these effects, that is, the substances that are active in this tetrad model, are considered as possessing an affinity for the cannabinoid receptors.

It has also been shown that cannabinoid receptor antagonists are highly effective in blocking the effects of a cannabinoid agonist in the mouse tetrada model. The tetrada model is described, for example, in the publication of A. C. Howlett et al, International Union of Pharmacology XXVII. Classification of Cannabinoid Receptors, Pharmacol Rev 54, 161-202, 2002 and David R. Compton et al., "In-vivo Characterization of a Specific Cannabinoid Antagonist Receptor (SR141716A): Inhibition of Tetrahydrocannabinol-induced Responses and Apparent Agonist Activity", J. Pharmacol, Exp. Ther 277, 2, 586-594, 1996. The corresponding parts of the description are incorporated by reference Material and Methods In the following experiments, male RMNI mice with weights of 20-30 g (Harian) were used. , Barcelona, Spain) The mice were acclimated to the experimental environment before applying the behavioral procedures mentioned below, and pre-treatment control values were determined for hot plate analgesia (in seconds), rectal temperature, sedation and catalepsy.

To determine the agonist activity of the substance tested, the mice were injected intravenously with the tested substance or vehicle alone. 15 minutes after injection, the latency of hot plate analgesia was measured. 20 minutes after the injection rectal temperature was measured, sedation and catalepsy. To determine the antagonist activity, the same procedure was used as in the determination of the agonist effects, with the difference that the substance in which the antagonist activity was evaluated was injected 5 minutes before the intravenous injection of 1.25 mg / kg of Win. -55,212, a known agonist of cannabinoid receptors. Analgesia in hot plate Analgesia in hot plate is determined according to the method described in Woolfe D. et al. "The evaluation of analgesic action of pethidine hydrochloride (Demerol)", J. Pharmacol. Exp. Ther.80, 300-307, 1944. The respective bibliographic description is incorporated by reference and forms part of the disclosure. a hot plate (Harvard Analgesimeter) at 55 ± 0.5 ° C until they show a painful sensation licking their legs or jumping, registering the time until these sensations appear. This reading is considered basal value (B). In the absence of a painful response, the maximum time allowed for the mice to remain on the hot plate is 40 seconds to avoid skin lesions. This period is called threshold time (PC). Fifteen minutes after administration of the tested substance, the mice are returned to the hot plate and the procedure described above is repeated. This period is called post-treatment reading (PT). The degree of analgesia is determined from the formula: MEF analgesia = (PT-B) / (PC-B) x 100 MEF = Maximum possible effect.

Determination of sedation and ataxia Sedation and ataxia are determined according to the method described in Desmet L. K. et al. "Anticonvulsive properties of Cinarizine and Flunarizine in Rats and Mice", Arzneim -Forsch. (Frug Res) 25, 9, 1975. The respective bibliographic description is incorporated as a reference and forms part of the description.

The scoring system chosen is 0: without ataxia; 1: doubtful; 2: manifest calm and tranquility; 3 pronounced ataxia; both before and after the treatment. The percentage of sedation is determined from the formula: Sedation% = arithmetic mean / 3 X 100 Hypothermia: Hypothermia is determined according to the method described in David R. Compton et al. "In-vivo Characterization of a Specific Cannabinoid Antagonist Receptor (SR141716A) Inhibition of Tetrahydrocannabinol-induced Responses and Apparent Agonist Activity", J. Pharmacol Exp Ther 277, 2, 586-594, 1996. The respective bibliographic description is incorporated as reference and is part of the description.The basal rectal temperatures are determined with a thermometer (Yellow Springs Instruments Co., Panlabs) and a thermistor probe inserted at 25mm before administering the tested substance.The rectal temperature is re-measured 20 minutes after the test. administration of the tested substance The temperature difference in each animal is calculated, considering that differences = -2 ° C represent activity.

Catalepsy: Catalepsy is determined according to the method described in Alpermann H. G. et al. "Pharmacological effets of Hoe 249: A new potential antidepressant", Drugs Dev. Res. 25, 267-282, 1992. The respective bibliographic description is incorporated as a reference and forms part of the description.

The cataleptic effect of the tested substance is evaluated based on the duration of the catalepsy, placing the animals head down with the hind legs on top of the block of wood.

The scoring system chosen is: Catalepsy during: More than 60 seconds = 6; 50 -60 seconds = 5, 40-50 seconds = 4, 30-40 seconds = 3, 20-30 seconds = 2, 5-10 seconds = 1, and less than 5 seconds = 0. The percentage of catalepsy is determined from the following formula:% Catalepsy = arithmetic mean / 6 X 100 The present invention is illustrated below by examples. These illustrations are provided solely by way of examples and in no way limit the general spirit of the present invention. Examples: The following examples (a) - (i) show the preparation of selected intermediates used in the synthesis of the azetidine compounds of the present invention. (a) .- threo-3-Bromo-l / 2-epoxybutane. To a solution of 20.4 g (0.284 mol) of trans-2-buten-l-ol in 60 ml of chloroform was added Br2 dropwise until the solution took a slight color (theoretical amount of Br2: 45.4 g). , 0.284 mol). Then crotyl alcohol was added dropwise until the solution became clear again. This reaction mixture was kept at room temperature (about 25 ° C) for 15 minutes, the solvent was allowed to evaporate and a dark liquid residue was obtained. This crude 2,3-dibromo-l-butanol was dissolved in 140 ml of diethyl ether and to the resulting solution was added 16 g (0.284 mol) of potassium hydroxide in 170 ml of water. The mixture was stirred for 2 hours at room temperature, the two layers were separated and the organic layer was washed with water. The solvent and the vacuum distillate were allowed to evaporate to obtain 24 g (56% of theory) of threo-3-bromo-1,2-epoxybutane with a boiling point of 55-60 ° C at 25 mm Hg. aH NMR (CDC13, d): 1.68 (d, 3H, J = 7 Hz); 2.69 (dd, ÍH, J = 5 and 2.5 Hz); 2.88 (dd, 1H, J = 5 and 4 Hz); 3.18 (ddd.lH, J = 7, 4 and 2.5 Hz); 3.86 (q. ÍH, J = 7 Hz) (b) .- trans-l-Diphenylmethyl-3-hydroxy-2-methylazetidine. A solution of threo-3-bromo-1,2-epoxybutane (9.8 g, 64.90 mmol) and aminodiphenylmethane (11.8 g, 64.5 mmol) in 70 ml of methanol was kept stirred for 80 hours at room temperature and 72 hours at reflux . The reaction mixture was then evaporated to dryness and the viscous residue was treated with diethyl ether and water. The aqueous layer was made alkaline with potassium carbonate and extracted with diethyl ether to obtain 9.4 g (61% of theory) of trans-1-diphenylmethyl-3-hydroxy-2-methylazetidine. The corresponding hydrochloride salt was obtained by dissolving a solution of the compound in an ethanol solution saturated with HCl gas and with subsequent removal of the solvent under vacuum. Melting point of hydrochloride: 100-103 ° C, IR (film, cm "1): 3400, 1450, 1156, 749. 702, XH NMR (CDC13, d): 0.75 (d, J = 6 Hz); 2.40 (b, 1H); 2. 56 (t, ÍH, J = 6 Hz); 3.02 (q.1H, J = 6 Hz); 3.64 (t, 1H, J = 6 Hz); 3.87 (quint., ÍH, J = 6 Hz); 4.34 (s, ÍH); 7.27 (m.10) H). (c) trans-1-Diphenylmethyl-2-methyl-3-methylsulfonyloxyazetidine. To a solution of 77.33 g (0.329 mol) trans-1-diphenylmethyl-3-hydroxy-2-methylazetidine in 600 ml of dichloromethane was added 50 g (0.495 mol) of triethylamine and the resulting mixture was cooled to 0 ° C. the temperature was maintained, a solution of 50 g (0.437 mol) of mesyl chloride was added dropwise and the resulting mixture was allowed to stir for 24 hours at room temperature. The resulting solution was washed twice with water (300 ml), dried with anhydrous sodium sulfate and evaporated to obtain an oil which, when crystallized with petroleum ether, yielded 104.6 g (96% of theory) of trans-1- diphenylmethyl-2-methyl-3 ^ methylsulfonyloxyazididine with a melting point of 68-71 ° C. IR (film, cm "1): 1361, 1339, 1178, 1152, 708, XH NMR (CDC13, d): 0.63 ( d, 3H, J = 7 Hz), 2.85 (t.1H, J = 6 Hz), 2.96 (s, 3H), 3.62 (t, 2H, J = 6 Hz), 4.39 (s.1H); 4.55 (quint., 1H, J = 6 Hz); 7.23 (m, 10H). (d) trans-3-Amino-l-diphenylmethyl-2-methylazetidine In a mixture of 150 ml of isopropanol and 100 ml of aqueous solution of ammonia at 30% (w / w), 31 g (93.65 mmol) of trans was dissolved. -l-diphenylmethyl-2-methyl-3-methylsulfonyloxyazetidine. The resulting solution was heated at 70 ° C for 2-3 hours while the reaction was monitored by thin layer chromatography. After the reaction was completed, the reaction mixture was allowed to evaporate until the isopropanol was completely removed (approximately 1/3 of the volume), extracting the residue with diethyl ether and water. The aqueous layer was basified and extracted with dichloromethane to obtain 10 g of the desired compound. The etheric layer of the first extraction was acidified with 5% (volume / volume) diluted acetic acid, the acid layer was made alkaline with sodium hydroxide and extracted with dichloromethane to obtain 6.3 g of the compound, giving a total of 16.3 g ( 70% of theory) of trans-3-amino-1-diphenylmethyl-2-methylazetidine with a melting point of 68-69 ° CPf of the corresponding dihydrochloride: 150-153 ° C, IR (film, cm "1): 3270, 1450. 702, XH NMR (CDC13, d): 0.64 (d, 3H, J = 7 Hz), 2.20 (q, 1H , J = 7 Hz), 2.63 (t, ÍH, J = 7 Hz), 2.90 (quiñi, 1 H, 3 = 1 Hz), 3.50 (t, ÍH, J = 7 Hz), 4.20 (s, ÍH 7.20 (m, 10H). (e) .- (2S, 3R) -l-Diphenylmethyl-2-methyl-3-methylsulphonyloxyazetidine The (2S, 3R) -l-diphenylmethyl-2-methyl-3-methylsulfonyloxyazididine enantiomer was obtained by the same procedure described above for the preparation of the trans-racemate, but using (2S, 3R) -1-diphenylmethyl-3-hydroxy-2-methylazetidine. The compound (2S, 3R) -l-diphenylmethyl-3-hydroxy-2-methylazetidine was obtained through the optical resolution of trans-1-diphenylmethyl-3-hydroxy-2-methylazetidine with (+) - (SS) - Camphorsulfonic acid, as described in the publication of J. Frigola et al., J. Med. Chem., 1995, 38, 1203-1215. (f) .- (2S, 3R) -3-amino-1-diphenylmethyl-2-methylazetidine The compound (2S, 3R) -3-amino-1-diphenylmethyl-2-methylazetidine was obtained as described above in (d), using (2S, 3R) -l-diphenylmethyl-2-methyl-3-methylsulfonyloxyazetidine. (g) - (2S, 3R) -N- (1-Benzhydryl-2-methyl-azetidin-3-yl) -2,2,2-trifluoro-asetamide To a solution of (2S, 3R) -3-amino-1- diphenylmethyl-2-methylazetidine (16.6 g, 65.9 mmol) in dichloromethane (90 ml) was added, dropwise, with stirring and cooling to about 0 ° C, a solution of trifluoroacetic anhydride (18.3 ml. , 131.7 mmoles) in 25 ml of dichloromethane. After the addition was complete, the reaction mixture was stirred at room temperature for two hours, ice water was added and the different phases were separated. The organic phase was washed with a 10% (w / w) sodium bicarbonate solution, followed by a saturated solution of sodium chloride, dried and evaporated to dryness under reduced pressure to obtain 23.35 g (yield 92% of theory) of (2S, 3R) -N- (1-Benzhydryl-2-methyl-azetidin-3-yl) -2,2,2-trifluoroacetamide in the form of oil.

IR (film, cm "1): 3260, 1710, 1660, 1230.

Said product was dissolved in dry ethanol and a solution of hydrochloric acid gas in diethyl ether was added, evaporating the resulting solution to dryness. The corresponding hydrochloride was obtained as a white solid with a melting point of 208-212 ° C.

IR of the hydrochloride (KBr, cm "1): 3319, 1700, 1562, 1213, 1187, 700. (h). - (2S, 3R) -2,2,2-Trifluoro-N- (2-methyl-azetidin-3-yl) -acetamide, hydrochloride 21.9 g (57 mmol) of (2S, 3R) -N hydrochloride - (1- Benzhydryl-2-methyl-azetidin-3-yl) -2,2,2-trifluoroacetamide were dissolved in 300 ml of methanol, Pd (OH) 2 / C was added. (20%, 4.4 g, 50% humidity), and the resulting mixture was treated with H2 at room temperature under 150 psi pressure for 15 minutes. The reaction mixture was filtered, the solvent was allowed to evaporate and the residue was washed with toluene to obtain 12.3 g (99% yield) of (2S, 3R) -2, 2, 2-trifluoro-N- (2-methyl- azetidin-3-yl) -acetamide with a melting point of 219-221 ° C.

IR (KBr, cm "1): 3244, 2895, 1727, 1563, 1213, 1177 (i) - Bis- (4-chlorophenyl) methyl bromide A solution of 4,4'-dichlorobenzhydrol (5 g, 19.8 mmol) and acetyl bromide (6 ml, 80 mmol) in benzene (40 ml) was heated to reflux for three hours. The reaction mixture was evaporated to dryness, and the resulting solid (6.2 g, 100% yield) is used directly for the subsequent synthesis without purification.

XH NMR (CDC13, d): 6.2 (s, ÍH), 7.3 (d, J = 8.7Hz, 4H), 7.36 (d, J = 8.7Hz, 4H).

Example 1: 4-Fluoro-benzenesulfoniso-trans-1- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl ester (la) 2,2-dimethyl-propionic acid- trans-l-benzhydril-2-methyl-azetidin-3-yl ester To a solution of the trans-1-benzhydryl-2-methyl-azetidin-3-ol hydrochloride salt (3.73 g, 12.8 mmol) prepared according to example (b) indicated above in 80 ml of pyridine, they added 4.4 ml of triethylamine and the mixture was cooled to approximately 0 ° C. Next, a solution of 2.4 ml (19.2 mmol) of trimethylacetyl chloride (pivaloyl chloride) was added, and the reaction mixture was heated to about 70 ° C under an inert gas atmosphere for eight hours. The solvent was allowed to evaporate, and the residue was dissolved in diethyl ether, washed with water, and the ether was evaporated to obtain the free base.

X H NMR (CDCl 3, d): 0.8 (d, J = 6.3 Hz, 3H), 1.2 (s, 9H), 2.6 (m, HH), 3.15 (m, HH) , 3.7 (dd, J = 7.0 and 7.5 Hz, ÍH), 4.3 (s, ÍH); 4.6 (dd, J = 6.0, 6.6 and 12.6 Hz), 7.25 (m, 6H), 7.4 (m, 4H). The crude was dissolved in 15 ml of ethanol, adding a solution of hydrochloric acid gas in ethanol to precipitate the hydrochloride salt, which was filtered and washed with diethyl ether to obtain 3.95 g (yield 85% of theory) of the hydrochloride salt. , with a melting point of 163 - 166 ° C.

XR NMR (d6-DMSO, d): 1.15 (s + d, 12H), 3.8 (m, 1H), 4.2 (m, 1H), 4.6 (m, 1H), 4, 9 (m, lH), 5.8 (d, J = 10 Hz, ÍH), 7.4 (m, 6H), 7.75 (m, 4H), 12.2 (s, ÍH) (lb) 2, 2-dimethyl-propionic acid (trans-2-methyl-azetidin-3-yl) ester hydrochloride 2,2-dimethyl-propionic acid 2-methyl-azetidin-3-yl ester hydrochloride was obtained from compound obtained according to step (a) after the treatment described in example (h) indicated above (yield 94% of theory).

XR NMR (CDCl 3, d): 1.2 (s, 9H), 1.7 (d, J = 6.9 Hz, 3H), 3.9 (m, HH), 4.2 (m, 1H) , 4.4 (m, HH), 4.9 (m, HH), 9.8-10.1 (b, 2H). (le) trans-1- [Bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl-2,2-dimethyl-propionic acid Said compound was obtained according to the method described in the example 2 presented below using bis- (4-chlorophenyl) methyl bromide prepared according to example (i) above (yield 95% of theory). XH NMR (CDC13, d): 0.8 (d, J = 6.5 Hz, 3H), 1.2 (s, 9H), 2.6 (m, 1H), 3.15 (m, 1H) , 3.7 (m, 1H), 4.3 (s, 1H), 4.6 (m, ÍH), 7.2-7.35 (m, 8H) (Id) 1- [Bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-ol This compound was obtained by hydrolysis of the ester prepared according to the step (le) indicated above, dissolving in ethanol that contained 10% by weight of sodium hydroxide. The reaction mixture was kept at room temperature (approximately 25 ° C) overnight. 1- [Bis- (-chloro-phenyl) -methyl] -2-methyl-azetidin-3-ol was obtained in a yield of 89%.

XH NMR (CDC13, d): 0.8 (d, J = 6.2 Hz, 3H), 2.5 (m, HH), 3.0 (m, HH), 3.6 (m, HH) , 3.9 (m, ÍH), 4.3 (s, ÍH), 7.2-7.3 (m, 8H) (le) Ester trans [1-bis- (4-chlorophenyl) -methyl] - 2-Methyl-3-azetidinol of 4-fluoro-benzenesulfonic acid Said compound was obtained according to the method described in Example 5 presented below. Melting point = 105-107 ° C, IR (KBr, cm "1): 1494, 1370, 1187, 1159, 1089, 1015, aH NMR (CDC13, d): 0.7 (d, J = 6.2 Hz, 3H), 2.7 (m, ÍH), 3.3 (m, 1H), 3.5 (m, ÍH), 4.3 (s, ÍH), 4.4 (m, ÍH), 7.2 (m, 10H), 7.9 (m, 2H).

Example 2 (2R, 3S) -N-. { l- [Bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} -2, 2, 2-trifluoroacetamide A mixture of bis- (4-chlorophenyl) methyl bromide (4 g, 12.6 mmol), (2R, 3S) -2-methyl-3-trifluoroacetylamino azetidine hydrochloride ( 2.3 g, 10.5 mmol) and potassium carbonate (16.5 g, 120 mmol) in 400 ml of acetonitrile was heated at reflux for 24 hours. The reaction mixture was filtered and the resulting clear solution was evaporated to dryness. The crude was crystallized from ethyl acetate to obtain 2.9 g of the product. Another 0.4 g of the product was obtained by treating the mother liquor. The overall yield of the compound (2R, 3S) -N-. { l- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} -2,2,2-trifluoroacetamide was 3.3 g (yield 67% of theory). IR (KBr, cm "1): 3262, 3080, 1678, 1495, 1200, 1080, 799, XE NMR (d6-DMS0 + TFA, d): 1.0 (d, J = 5.6 Hz, 3H). 3.95, dd, J = 6.8 and 17.9 Hz, HI), 4.3 (2dd, 2H), 4.6 (dd, J = 6.8 and 13.2Hz, HI), 5.7 (s, ÍH), 7.4-7.5 (m, 8H), 9.8 (d, J = 5.3Hz, ÍH).

Example 3 (2R, 3S) -1- [Bis- (4-chlorophenyl) methyl] -2-methyl-azetidin-3-yl amine (2R, 3S) -N-. { l- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} -2,2,2-trifluoro-acetamide (2.8 g, 6.7 mmol) ) was suspended in a sodium hydroxide solution (25 ml, «60 mmol) and 60 ml of ethanol and stirred at room temperature (approximately 25 ° C), observing the gradual dissolution until obtaining a transparent solution. After three hours, the solvent was evaporated under reduced pressure and the resulting basic solution was extracted with ethyl acetate, washed with water, dried with sodium sulfate and evaporated to dryness. (2R, 3S) -1- [Bis- (4-chlorophenyl) methyl] -2-methyl-azetidin-3-yl amine was obtained as an oil (1.95 g, yield 91% of theory). IR (KBr, cm "1): 3369, 1495, 1110, 1030, 790, aH NMR (CDC13, d): 0.75 (d, J = 5.8Hz, 3H), 2.3 (m, 1H) , 2.7 (m, ÍH), 3.0 (m, ÍH), 3.6 (m, ÍH), 4.2, (s, ÍH), 9, 7.2-7.3 (m, 8H) The product was dissolved in an ethanolic solution saturated with hydrochloric acid gas and then the solvent was evaporated to obtain the corresponding dihydrochloride salt., cm "1): 3380, 1488, 1094, 1014 [] D -35.5 (c 1.0, MeOH) Example 5 (2S, 3R) -N-. {1- [Bis- (4-chlorophenyl ) methyl] -2-methylazetidin-3-yl.} -4-fluoro-benzene sulfonamide It was dissolved (2R, 3S) -1- [bis- (4-chlorophenyl) methyl] -2-methyl-azetidin-3- amine (0.15 g, 0.47 mmol) and triethylamine (84 μl, 0.59 mmol) in anhydrous tetrahydrofuran (6 ml) The mixture was cooled in an ice bath to 0 ° C and a mixture was added dropwise. solution of 4-benzenesulfonyl chloride (0.11 g, 0.54 mmol) in THF (4 ml) The cooling bath was removed, the reaction mixture was allowed to warm to room temperature (ca. C) and stirred until the next day, the solvent was removed under reduced pressure and the residue redissolved in ethyl acetate and water.The organic solution was washed with a saturated solution of sodium bicarbonate, water, dried with sodium sulfate and evaporated to dryness 0.16 g of (2R, 3S) -1-N-. {l- [bis- (4-chlorophenyl) meti was obtained. l] -2-methylazetidin-3-yl} -4-fluorobenzenesulfonamide (yield 75% of theory) with a melting point of 154-157 ° C. IR (KBr, cm "1): 3255, 1592, 1492, 1155, 1090, 802. X NMR (CDC13, d): 0.6 (d, J = 5.8 Hz, 3H), 2.3 (m, ÍH), 2.9 (m, ÍH), 3.4 (m, 2H), 4.2 (s, ÍH), 4.8 (d, J = 8.4Hz, ÍH), 7.1-7 , 25 (m, 10H), 7.8 (m, 2H). [A] D -61.5 (c 1.0, MeOH) The following table shows the compounds prepared according to examples 1, 2 , 3 and 5 indicated above Also included are examples of compounds 4 and 6-31, prepared by analogous methods.

Table 1: fifteen twenty 10 fifteen twenty Pharmacological data: I. In-vitro determination of affinity for CB1 / CB2 receptors The affinity of azetidine compounds substituted by CB1 / CB2 receptors is determined as described above. Table II below shows some of the values obtained: Table II: II. In-vivo bioassay system for the determination of cannabinoid activity The in-vivo determination of cannabinoid activity was performed as described above. The following table shows some of the values obtained: Table III: i.v. intravenous A: Hot plate test B: Hypothermia C: Catalepsy D: Sedation As the values in Table III show, the azetidine compounds of the present invention act as antagonists of cannabinoid receptors, particularly of CBx receptors.

Claims (31)

1. NOVELTY OF THE INVENTION Having described the invention as above, the content of the following CLAIMS is claimed as property 1. Substituted azetidine compounds of general formula I, wherein R1 represents an optionally at least monosubstituted phenyl group, R2 represents a cycloaliphatic, saturated or unsaturated group, which may be optionally at least monosubstituted, optionally containing at least one heteroatom as ring member, which may be fused to an optionally at least monosubstituted mono- or polycyclic ring system, or an optionally at least monosubstituted aryl or heteroaryl group, which may be fused with an optionally at least monosubstituted mono- or polycyclic ring system, R3 represents a linear or branched aliphatic group, saturated or unsaturated, optionally at least monosubstituted, a cycloaliphatic, saturated or unsaturated group, which may optionally be at least monosubstituted, optionally containing at least one heteroatom as ring member, which may be fused with a mono- or ring system polycyclic and / or linked via an alkylene group li neal or branched, or an optionally at least monosubstituted aryl or heteroaryl group, which may be fused with a mono- or polycyclic ring system and / or linked via a straight or branched alkylene group, with the proviso that R3 is linked to the azetidinic ring through a carbon atom, R4 represents a hydrogen atom, a cyano group, a carboxy group, a linear or branched alkyl group, or an optionally at least monosubstituted aryl group, R5 represents a group -0-S02- R6, a group -NH-CO-R7, a group -NH2, a group -NH-S02-R8, a group -NR9-S02-R10 or a group -O-CO-R11, R6 represents a linear aliphatic group or branched, saturated or unsaturated, optionally at least monosubstituted, a cycloaliphatic, saturated or unsaturated group, which may optionally be at least monosubstituted, optionally containing at least one heteroatom as ring member, which may be fused with a mono ring system - or polycyclic co and / or linking via a linear or branched alkylene group, or an optionally at least monosubstituted aryl or heteroaryl group, which may be fused with a mono- or polycyclic ring system and / or linked via a straight or branched alkylene group, R7 represents a linear or branched, saturated or unsaturated aliphatic, optionally at least monosubstituted, cycloaliphatic, saturated or unsaturated group, which may optionally be at least monosubstituted, optionally containing at least one heteroatom as ring member, which may be condensed with a mono- or polycyclic ring system and / or linked via a linear or branched alkylene group, or an optionally at least monosubstituted aryl or heteroaryl group, which may be fused with a mono- or polycyclic ring system and / or linked via a linear or branched alkylene group, R8 represents a linear or branched, saturated or unsaturated aliphatic group, optionally at least monosubstituted, a cycloaliphatic, saturated or unsaturated group, which may optionally be at least monosubstituted, optionally containing at least one heteroatom as ring member, which may be fused with a mono- or polycyclic ring system and / or linked via a linear or bridged alkylene group, and / or in the form of a bridge by a linear or branched alkylene group, or an optionally at least monosubstituted aryl or heteroaryl group, which may be fused with a mono- or ring system polycyclic and / or linked via a linear or branched alkylene group, R9 represents a group -S02-R12, a group -CO-R13, a linear or branched, saturated or unsaturated aliphatic group, optionally at least monosubstituted, a cycloaliphatic, saturated group or unsaturated, which may optionally be at least monosubstituted, optionally containing at least one heteroatom as ring member, which may be fused with a mono- or polycyclic ring system and / or linked via a straight or branched alkylene group and / or in the form of a bridge by a linear or branched alkylene group, or an optionally at least monosubstituted aryl or heteroaryl group, which may be fused with a mono- or polycyclic ring system and / or linked via an alkylene group, R10 represents an aliphatic group linear or branched, saturated or unsaturated, optionally at least monosubstituted, a cycloaliphatic, saturated or unsaturated group, which may optionally be at least monosubstituted, optionally containing at least one heteroatom as ring member, which may be fused to a system mono- or polycyclic ring and / or link via a linear or bridge-shaped alkylene group, and / or be in the form bridge by a linear or branched alkylene group, or an optionally at least monosubstituted aryl or heteroaryl group, which may be fused with a mono- or polycyclic ring system and / or linked via a straight or branched alkylene group, R11 represents a group aliphatic linear or branched, saturated or unsaturated, optionally at least monosubstituted, a cycloaliphatic, saturated or unsaturated group, which may optionally be at least monosubstituted, optionally containing at least one heteroatom as ring member, which may be fused to a mono- or polycyclic ring system and / or linking via a linear or bridged alkylene group, and / or in the form of a bridge by a linear or branched alkylene group, or an optionally at least monosubstituted aryl or heteroaryl group, which it may be condensed with a mono- or polycyclic ring system and / or linked via a linear or branched alkylene group, R12 rep represents a linear or branched, saturated or unsaturated aliphatic, optionally at least monosubstituted, cycloaliphatic, saturated or unsaturated group, which may optionally be at least monosubstituted, optionally containing at least one heteroatom as ring member, which may be condensed with a mono- or polycyclic ring system and / or linked via a linear or bridged alkylene group, and / or bridged by a linear or branched alkylene group, or an optionally at least monosubstituted aryl or heteroaryl group , which may be condensed with a mono- or polycyclic ring system and / or linked via a linear or branched alkylene group, R13 represents a linear or branched, saturated or unsaturated aliphatic group, optionally at least monosubstituted, a cycloaliphatic, saturated or unsaturated, which may optionally be at least monosubstituted, optionally containing at least one heteroatom or as ring member, which may be fused with a mono- or polycyclic ring system and / or linked via a linear or bridged alkylene group, and / or be bridged by a straight or branched alkylene group, or an optionally at least monosubstituted aryl or heteroaryl group, which may be fused with a mono- or polycyclic ring system and / or linked via a straight or branched alkylene group, optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any mixture ratio, or one of its corresponding N-oxides, one of its corresponding salts, or one of its corresponding solvates , with the proviso that compounds of general formula I, in which R1 and R2 each represent an unsubstituted phenyl group, R5 represents a group -0-S02-R6 and R 6 represents a methyl group, are excluded.
2. 2. Compounds, according to claim 1, characterized in that R1 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a halogen atom, a linear or branched C6-6 alkyl group , a linear or branched C6-alkoxy group, a formyl group, a hydroxy group, a trifluoromethyl group, a trifluoromethoxy group, an alkyl group -CO-C? -6, a cyano group, a carboxy group, an alkyl group -CO-0-C? -6, a -CO-NRARB group, a -CO-NH-NRcRD group, an S-Cx_6 alkyl group, an alkoyl group -SO-Cx_6, an alkyl group -S02-Cx.6 / an alkenyl group -Cx-6 alkyl S-Cx-6, an alkylene group -Cx-6-alkyl -S0-C? _6, an algerylene group -C? _6-alkyl -S02-C? 6, a group Cx-6 alkyl substituted by one or more hydroxy groups and an alkylene group -Cx_6-NRERF, in which RA, RB, identical or different, represent hydrogen or a C? -6 alkyl group, or RA and RB together with the atom nitrogen bridge s orman a saturated monocyclic or bicyclic, 3- to 10-membered heterocyclic ring system which may be at least monosubstituted by one or more identical or different C 1-6 alkyl groups, and / or which may contain at least one additional heteroatom selected from group consisting of nitrogen, oxygen and sulfur as ring member, Rc, RD, identical or different, represents a hydrogen atom, a CX-6 alkyl group, an alkyl group -CO-O-C? -6, a group C3_8 cycloalkyl, a C3_8 alkoxy group, a C3_8 cycloalkyl group, a C? -6 alkynyl group, or a C? _6 alkyl group substituted by one or more hydroxy groups, or R, RD together with the Nitrogen bridge atom forms a saturated monocyclic or bicyclic 3- to 10-membered heterocyclic ring system, which may be at least monosubstituted by one or more substituents independently selected from the group consisting of a CX-6 alkyl group, an alkyl group -CO-Cx_6, an alkyl group -CO-O-Cx-6, a group or alkenyl -CONH- Cx_6, an alkyl group -CS-NH-Cx_6, an oxo group, a CX-6 alkyl group substituted by one or more hydroxy groups, an alkylene group Cx_6-alkyl 0-CX-6 and a group - CO-NH2 and / or which may contain at least one additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur as ring member, and in which RE, RF, identical or different, represent hydrogen or a Cx_6 alkyl group, or RE and RF together with the nitrogen bridge atom form a saturated monocyclic or bicyclic 3- to 10-membered heterocyclic ring system, which may be at least monosubstituted by one or more CX_6 alkyl groups identical or different and / or which may be containing at least one additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur as ring member, preferably R1 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of n a fluorine atom, a chlorine atom, a bromine atom, a linear or branched Cx-6 alkyl group, a linear or branched Cx_6 alkoxy group, a formyl group, a hydroxy group, a trifluoromethyl group, a trifluoromethoxy group, a cyano group and a carboxy group, more preferably R1 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a methoxy group, a trifluoromethyl group and a trifluoromethoxy group, more preferably still R 1 represents a phenyl group, which is substituted by a chlorine atom at the 4-position.
3. 3. Compounds, according to claim 1 or 2, characterized in that R2 represents a saturated or unsaturated C3_8 cycloaliphatic group, which may optionally be at least monosubstituted, optionally containing at least one heteroatom as ring member, which may be fused with a mono- or polycyclic ring system optionally at least monosubstituted, or a 5 or 6 membered aryl or heteroaryl group, optionally at least monosubstituted, which may be fused with an optionally at least monosubstituted mono- or polycyclic ring system, preferably R2 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a halogen atom, a linear or branched CX-6 alkyl group, a linear or branched C? -6 alkoxy group, a formyl group, a hydroxy group, a trifluoromethyl group, a trifluoromethoxy group, an alkyl group -CO-C? _6, a cyano group, a carboxy group, an alguyl group -CO- 0-C? _6, a group -CO-NRARB, a group -CO-NH-NRcRD, an alkyl group SC? -6, an alkyl group -SO-C? -6, an alkyl group -S02-C? 6, an alkylene group -C? -6-alkyl SC? -6, an alkylene group -C? _6-alkyl -SO-C? -6, an alkylene group -C? -6-alkyl -S02-C? _6 , a C? -6 alkyl group substituted by one or more hydroxy groups and an alkylene group -C? _6-NRERF, in which RA, RB, identical or different, represent hydrogen or a C? _6 alkyl group, or RA and RB together with the nitrogen bridge atom form a 3- to 10-membered, mono- or bicyclic, saturated heterocyclic ring system, which may be at least monosubstituted by one or more C?-6 alkyl groups identical or different and / or which may be contain at least one additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur as ring member, Rc, RD, identical or different, represents a hydrogen atom, a CX_6 alkyl group, a C0-0-Cx alkyl group -6, a C3-8 cycloalkyl group, a graph C8_6 alkylene C3_8-cycloalkyl, a CX-6 alkylene group, 0-Cx-6 alkyl or a CX_6 alkyl group substituted by one or more hydroxy groups, or Rc, RD together with the nitrogen bridge atom form a heterocyclic ring system of 3 to 10 members, mono- or bicyclic, saturated, which may be at least monosubstituted by one or more substituents independently selected from the group consisting of a CX-6 alkyl group, an -CO-CX-6 alkyl group, a alkoyl group -CO-O-CX-6, an alkyl group -CONH-C? _6, an alkyl group -CS-NH-Cx_6, an oxo group, a C? -6 alkyl group substituted by one or more hydroxy groups, an alkylene group Cx_6-alkyl-0-Cx_6 and a group -CO-NH2 and / or which may contain at least one additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur as ring member, and in which RE, RF, identical or different, represent hydrogen or a CX-6 alkyl group, or RE and RF together with the nitrogen bridge atom form a 3- to 10-membered heterocyclic ring system, mono- or bicyclic, saturated, which may be at least monosubstituted by one or more identical or different Cx-6 alkyl groups and / or which may contain at least one additional heteroatom selected from the group consisting in nitrogen, oxygen and sulfur as ring member, more preferably R2 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a fluorine atom, a chlorine atom, an atom of bromine, a methyl group, a methoxy group, a trifluoromethyl group and a trifluoromethoxy group, more preferably still R2 represents a phenyl group, which is substituted by a chlorine atom in the 4-position.
4. 4. Compounds, according to one or more of claims 1-3, characterized in that R3 represents a linear or branched, saturated or unsaturated Cx-X0 aliphatic group, optionally at least monosubstituted, a C3-8 cycloaliphatic group, saturated or unsaturated, which may optionally be at least monosubstituted, optionally containing at least one heteroatom as ring member, which may be fused with a mono- or polycyclic ring system and / or may be linked via a linear Cx_6 alkylene group or branched, or a 5 or 6 membered aryl or heteroaryl group, optionally at least monosubstituted, which may be fused with a mono- or polycyclic ring system and / or may be linked via a straight or branched Cx_6 alkylene group, preferably R3 represents a straight or branched Cx_x alkyl group, optionally at least monosubstituted, or a 5- or 6-membered aryl or heteroaryl group, optionally at least monosubstituted, which may be fused with a mono- or polycyclic ring system and / or may be linked via a linear or branched Cx-6 alguylene group, more preferably R3 represents a linear or branched, unsubstituted Cx-X0 alkyl group, more preferably and still R3 represents a methyl group.
5. 5. Compounds according to one or more of claims 1-4, characterized in that R4 represents a hydrogen atom, a cyano group, a carboxy group, a linear or branched Cx-X0 alkyl group, or an aryl group of 5 or 6 members, optionally at least monosubstituted, preferably R4 represents a hydrogen atom, a linear or branched Cx_3 alkyl group, or an optionally at least monosubstituted phenyl group, more preferably R4 represents a hydrogen atom or a CX-3 alkyl group linear or branched, more preferably still R4 represents a hydrogen atom.
6. 6. Compounds according to one or more of claims 1-5, characterized in that R5 represents a group -0-S02-R6, a group -NH-CO-R7, a group -NH2, a group -NH- S02-R8 or a group -NR9-S02-R10, preferably R5 represents a group -0-S02-R6, a group -NH-SO2-R8 or a group -NR9-S02-R10.
7. 7. Compounds according to one or more of claims 1-6, characterized in that R6 represents a linear or branched, saturated or unsaturated, optionally at least monosubstituted, a saturated or unsaturated cycloaliphatic group; which may optionally be at least monosubstituted, optionally containing at least one heteroatom as ring member, which may be fused with a mono- or polycyclic ring system and / or may be linked via a straight or branched C6-6 alkylene group, or an optionally at least monosubstituted 5 or 6-membered aryl or heteroaryl group, which may be fused with a mono- or polycyclic ring system and / or may be linked via a linear or branched C6-6 alkylene group, preferably R6 represents a optionally at least monosubstituted cycloaliphatic C3_8 group or an optionally at least monosubstituted phenyl group, in which the respective substituents are independently selected of the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a linear or branched Cx_6 alkyl group, a linear or branched Cx_6 alkoxy group, a formyl group, a hydroxy group, a trifluoromethyl group, a trifluoromethoxy group, a cyano group and a carboxy group, more preferably R6 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a fluorine atom, a chlorine atom, an atom of bromine, a methyl group, a methoxy group, a trifluoromethyl group and a trifluoromethoxy group.
8. 8. Compounds, according to one or more of claims 1-7, characterized in that R7 represents a linear or branched, saturated or unsaturated, optionally at least monosubstituted, C3.8 cycloaliphatic, saturated or unsaturated Cx.sub.x. unsaturated, which may optionally be at least monosubstituted, optionally containing at least one heteroatom as ring member, which may be fused with a mono- or polycyclic ring system and / or may be linked via a linear Cx-6 alkylene group or branched, or an optionally at least monosubstituted aryl or heteroaryl group, which may be fused with a mono- or polycyclic ring system and / or may be linked via a linear or branched Cx-6 alkylene group, preferably R7 represents a linear Cx_5 alkyl group or branched, optionally at least monosubstituted, a saturated C5_6 cycloaliphatic group, optionally at least monosubstituted, or an optionally at least monosubstituted phenyl group, more preferably R7 represents a linear or branched Cx.5 alkyl group, optionally at least monosubstituted, a C5_6 cycloaliphatic group saturated, optionally at least monosubstituted, or an optionally at least monosubstituted phenyl group, in which, in each case, the substituents are selected, independently of one another, from the group consisting of a fluorine atom, a chlorine atom, an bromine atom, a methyl group, a methoxy group, a trifluoromethyl group and a trifluoromethoxy group.
9. 9. Compounds according to one or more of claims 1-8, characterized in that R8 represents a Cx.xo or linear or branched, saturated or unsaturated aliphatic group, optionally at least monosubstituted, a C3.8 cycloaliphatic group, saturated or unsaturated, which may optionally be at least monosubstituted, optionally containing at least one heteroatom as ring member, which may be fused with a mono- or polycyclic ring system and / or may be linked via a straight or a Cx_xo alkylene group and / or may be in bridging form by a linear or branched Cx-5 alkylene group, or an optionally at least monosubstituted 5 or 6-membered aryl or heteroaryl group, which may be fused with a mono- or ring system polycyclic and / or can be linked via a linear or branched Cx_x alkylene group, preferably R8 represents a linear or branched Cx_x3 alkyl group, a C5-6 cycloaliphatic group, saturated or in saturated, which may optionally be at least monosubstituted, optionally containing at least one heteroatom as a member of the ring, which may be fused with a mono- or polycyclic ring system and / or may be linked via a straight or a CX_3 alkylene group and / or may be bridged by a linear or branched Cx-3 alkylene group, or an optionally at least monosubstituted 5 or 6-membered aryl or heteroaryl group, which may be fused with a mono- or ring system polycyclic and / or can be linked via a linear or branched Cx_3 alkylene group, more preferably R8 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group, an optionally at least monosubstituted phenyl group, a benzyl group optionally at least monosubstituted, an optionally at least monosubstituted naphthyl group, which may be linked via an alkylene group Cx_3, an optionally at least monosubstituted thienyl group, an optionally at least monosubstituted group 2, 1,3-Benzothiadiazole, an optionally at least monosubstituted Benzo [b] thiophenyl group, an optionally at least monosubstituted Imidazo [2.lb] thiazole group, an optionally at least monosubstituted IH-pyrazole group or a 7, 7-Dimethyl-2-oxo-bicyclo- [2.2.1] -hept-1-yl group, more preferably still R8 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group , an optionally at least monosubstituted phenyl group, an optionally at least monosubstituted benzyl group, an optionally at least monosubstituted naphthyl group, which may be linked via an alkylene group Cx_3, an optionally at least monosubstituted thienyl group, a group 2.1.3- Benzothiadiazole optionally at least monosubstituted, an optionally at least monosubstituted Benzo [b] thiophenyl group, an optionally at least monosubstituted Imidazo [2.lb] thiazole group, an optionally at least monosubstituted lH-pyrazole group or a 7,7-Dimeti group l-2-oxo-bicyclo- [2.2.1] -hept-1-yl, in which said substituents, if present, are identical or different and are selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a formyl group, a phenyl group, a phenoxy group, a group phenoxy substituted by bromine at the 4-position and a methylsulfonyl group.
10. 10. Compounds according to one or more of claims 1-9, characterized in that R9 represents a -S02-R12 group, a -CO-R13 group, a linear or branched, saturated or unsaturated Cx-10 aliphatic group, optionally at least monosubstituted, a saturated or unsaturated C3_8 cycloaliphatic group, which may optionally be at least monosubstituted, optionally containing at least one heteroatom as ring member, which may be fused with a mono- or polycyclic ring system and / or it can be linked by a linear or branched Cx-6 alkylene group and / or in bridging form by a linear or branched Cx_6 alkylene group, or an optionally at least monosubstituted aryl or heteroaryl group, which may be fused with an annular system mono- or polycyclic and / or can be linked via an alkylene group Cx_6, preferably R9 represents a group -S02-R12, a linear or branched C1_10 alkyl group, or a phenyl group optionally at least mono substituted, which may be linked via an alkylene group Cx_2, more preferably R9 represents a group -S02-R12, a linear or branched Cx-3 alkyl group, or a phenyl group, which may be linked via a CX-2 alkylene group and / or to be substituted by one or more substituents independently selected from the group consisting of a fluorine atom, a chlorine atom and a bromine atom.
11. 11. Compounds according to one or more of claims 1-10, characterized in that R10 represents a linear or branched, saturated or unsaturated, optionally at least monosubstituted C3_x aliphatic group, a C3-8 cycloaliphatic group, saturated or unsaturated, which may optionally be at least monosubstituted, optionally containing at least one heteroatom as a ring member, which may be fused with a mono- or polycyclic ring system and / or may be linked via a straight or branched Cx_? 0 alkylene group bridge and / or may be bridged by a linear or branched Cx_5 alkylene group, or an optionally at least monosubstituted 5 or 6-membered aryl or heteroaryl group, which may be fused with a mono- or polycyclic ring system and or it can be linked via a linear or branched alkylene group C? _10, preferably R10 represents a linear or branched C? _? alkyl group, a C5-6 cycloaliphatic group, which can be optionally be at least monosubstituted, optionally containing at least one heteroatom as ring member, which may be fused with a mono- or polycyclic ring system and / or may be linked via a linear or bridged C 1 -C 3 alkylene group and / or it may be in bridged form by a linear or branched C 1 -C 3 alkylene group, or an optionally at least monosubstituted 5 or 6 membered aryl or heteroaryl group, which may be fused with a mono- or polycyclic ring system and / or can be linked via a straight or branched C? _3 alkylene group, more preferably R10 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group, an optionally at least monosubstituted phenyl group, a benzyl group optionally at least monosubstituted, an optionally at least monosubstituted naphthyl group, which may be linked via an alkylene group C? -3, an optionally at least monosubstituted thienyl group, a 2,1,3-Be group optionally at least monosubstituted nzothiadiazole, an optionally at least monosubstituted Benzo [b] thiophenyl group, an Imidazo [2. lb] thiazole optionally at least monosubstituted, an optionally at least monosubstituted lH-pyrazole group or a 7,7-Dimethyl-2-oxo-bicyclo- [2.2.1] -hept-1-yl group, more preferably still R10 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group, an optionally at least monosubstituted phenyl group, an optionally at least monosubstituted benzyl group, an optionally at least monosubstituted naphthyl group, which can be linked via an alkylene group C? _3, an optionally at least monosubstituted thienyl group, an optionally at least monosubstituted group 2, 1,3-Benzothiadiazole, an optionally at least monosubstituted Benzo [b] thiophenyl group, an optionally at least monosubstituted Imidazo [2.lb] thiazole group, an optionally at least monosubstituted lH-pyrazole group or a 7,7-Dimethyl-2-oxo-bicyclo- [2.2.1] -hept-1-yl group, in which said substituents, if present, are identical or different and are selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a formyl group, a phenyl group, a phenoxy group, a phenoxy group substituted by bromine at position 4 and a methylsulfonyl group.
12. 12. Compounds according to one or more of claims 1-11, characterized in that R11 represents a linear or branched, saturated or unsaturated, optionally at least monosubstituted C? _10 aliphatic group, a saturated or unsaturated C3_8 cycloaliphatic group, which may optionally be at least monosubstituted, optionally containing at least one heteroatom as ring member, which may be fused with a mono- or polycyclic ring system and / or may be linked via a linear CX_xo alkylene group or bridged and / or it may be in the form of a bridge by a straight or branched Cx_s alkylene group, or an optionally at least monosubstituted 5 or 6 membered aryl or heteroaryl group, which may be fused with a mono- or polycyclic ring system and / or it can be linked via a straight or branched Cx-X0 alguylene group, preferably R11 represents a linear or branched Cx_x3 alkyl group, a saturated C3-6 cycloaliphatic group or unsaturated, which may optionally be at least monosubstituted, optionally containing at least one heteroatom as ring member, which may be fused with a mono- or polycyclic ring system and / or may be linked via a linear Cx-3 alkylene group or in the form of a bridge and / or may be in the form of a bridge by a linear or branched Cx-3 alkylene group, or an optionally at least monosubstituted 5 or 6-membered aryl or heteroaryl group, which may be fused with an annular system mono- or polycyclic and / or can be linked via a linear or branched Cx_3 alkylene group, more preferably R11 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group, an optionally at least monosubstituted phenyl group, an optionally at least monosubstituted benzyl group, an optionally at least monosubstituted naphthyl group, which may be linked via a CX-3 alkylene group, an optionally at least monosubstituted thienyl group is an optionally at least monosubstituted group 2, 1,3-Benzothiadiazole, an optionally at least monosubstituted Benzo [b] thiophenyl group, an optionally at least monosubstituted Imidazo [2.lb] thiazole group, an optionally at least 1H-pyrazole group monosubstituted or a 7,7-Dimethyl-2-oxo-bicyclo- [2.2.1] -hept-1-yl group, more preferably still R 11 represents a methyl group, an ethyl group, an n-propyl group, a n-group -butyl, an optionally at least monosubstituted phenyl group, an optionally at least monosubstituted benzyl group, an optionally at least monosubstituted naphthyl group, which can be linked via an alkylene group Cx.3, an optionally at least monosubstituted thienyl group, a group 2, 1,3-Benzothiadiazole optionally at least monosubstituted, an optionally at least monosubstituted Benzo [b] thiophenyl group, an optionally at least monosubstituted Imidazo [2.lb] thiazole group, an optionally at least monosubstituted lH-pyrazole group or a group 7, 7 -Dimethyl-2-oxo-bicyclo- [2.2.1] -hept-1-il, wherein said substituents, if present, are identical or different and are selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a formyl group, a phenyl group, a phenoxy group, a phenoxy group substituted by bromine at the 4 position and a methylsulfonyl group.
13. 13. Compounds according to one or more of claims 1-12, characterized in that R12 represents a linear or branched, saturated or unsaturated Cx.xo aliphatic group, optionally at least monosubstituted, a C3-8 cycloaliphatic group, saturated or unsaturated, which may optionally be at least monosubstituted, optionally containing at least one heteroatom as ring member, which may be fused with a mono- or polycyclic ring system and / or may be linked via a linear Cx-X0 alguylene group or in the form of a bridge and / or may be in the form of a bridge by means of a linear or branched CX-5 alkylene group, or an optionally at least monosubstituted 5 or 6-membered aryl or heteroaryl group, which may be fused with a mono ring system - or polycyclic and / or can be linked via a linear or branched Cx_x alkylene group, preferably R12 represents a linear or branched Cx-X0 alkyl group, a saturated C5-6 cycloaliphatic group or unsaturated, which may optionally be at least monosubstituted, optionally containing at least one heteroatom as ring member, which may be fused with a mono- or polycyclic ring system and / or may be linked via a linear Cx-3 alkylene group or in the form of a bridge and / or may be in the form of a bridge by a linear or branched Cx-3 alkylene group, or an optionally at least monosubstituted 5 or 6-membered aryl or heteroaryl group, which may be fused with an annular system mono- or polycyclic and / or can be linked via a linear or branched Cx-3 alkylene group, more preferably R12 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group, a phenyl group optionally at least monosubstituted, an optionally at least monosubstituted benzyl group, an optionally at least monosubstituted naphthyl group, which may be linked via an alkylene group C3_3, an optionally at least monosubstituted thienyl group Uido, a group 2, 1,3-Benzothiadiazole optionally at least monosubstituted, an optionally at least monosubstituted Benzo [b] thiophenyl group, an Imidazo group [2. lb] thiazole optionally at least monosubstituted, an optionally at least monosubstituted lH-pyrazole group or a 7,7-Dimethyl-2-oxo-bicyclo- [2.2.1] -hept-1-yl group, more preferably still R12 represents a a methyl group, an ethyl group, an n-propyl group, an n-butyl group, an opsionally at least monosubstituted phenyl group, an optionally at least monosubstituted benzyl group, an optionally at least monosubstituted naphthyl group, which can be linked via an alkylene group Cx_3, an optionally at least monosubstituted thienyl group, a group 2, 1,3-Benzothiadiazole optionally at least monosubstituted, an optionally at least monosubstituted Benzo [b] thiophenyl group, an Imidazo group [2. lb] thiazole optionally at least monosubstituted, an optionally at least monosubstituted lH-pyrazole group or a 7,7-Dimethyl-2-oxo-bicyclo- [2.2.1] -hept-1-yl group, in which said substituents, if they are present, they are identical or different and are selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a formyl group, a phenyl group, a phenoxy group, a phenoxy group replaced by bromine at position 4 and a methylsulfonyl group.
14. 14. Compounds, according to one or more of claims 1-13, characterized in that R 13 represents a linear or branched, saturated or unsaturated, optionally at least monosubstituted C? -10 aliphatic group, a saturated or unsaturated C3-8 cycloaliphatic group, which may optionally be at least monosubstituted, optionally containing at least one heteroatom as a ring member, which may be fused with a mono- or polycyclic ring system and / or may be linked via a linear C? _? al alkylene group or in the form of a bridge and / or may be in the form of a bridge by means of a straight or branched C? _ al alkylene group, or an optionally at least monosubstituted 5 or 6-membered aryl or heteroaryl group, which may be fused with a mono ring system - or polycyclic and / or can be linked via a linear or branched C 1 - 1 alkylene group, preferably R 13 represents a linear or branched C x - x alkyl group, a C 5 - 6 cycloaliphatic group, saturated or saturated, which may optionally be at least monosubstituted, optionally containing at least one heteroatom as a member of the ring, which may be fused with a mono- or polycyclic ring system and / or may be linked via a straight or a Cx_3 alkylene group and / or may be bridged by a linear or branched Cx-3 alkylene group, or an optionally at least monosubstituted 5 or 6-membered aryl or heteroaryl group, which may be fused with a mono- or ring system polycyclic and / or can be linked via a linear or branched CX-3 alkylene group, more preferably R 13 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group, an optionally at least monosubstituted phenyl group, a optionally at least monosubstituted benzyl group, an optionally at least monosubstituted naphthyl group, which may be linked via an alkylene group Cx_3, an optionally at least monosubstituted thienyl group , an optionally at least monosubstituted 2, 1, 3-Benzothiadiazole group, an optionally at least monosubstituted Benzo [b] thiophenyl group, an optionally at least monosubstituted Imidazo [2.lb] thiazole group, an optionally at least monosubstituted lH-pyrazole group or a 7,7-Dimethyl-2-oxo-bicyclo- [2.2.1] -hept-1-yl group, more preferably still R 13 represents a methyl group, an ethyl group, an n-propyl group, a n-group butyl, an optionally at least monosubstituted phenyl group, an optionally at least monosubstituted benzyl group, an optionally at least monosubstituted naphthyl group, which can be linked via an alkylene group Cx_3, an optionally at least monosubstituted thienyl group, a group 2, 1,3 Benzothiadiazole optionally at least monosubstituted, an optionally at least monosubstituted Benzo [b] thiophenyl group, an Imidazo group [2. lb] thiazole optionally at least monosubstituted, an optionally at least monosubstituted lH-pyrazole group or a 7,7-Dimethyl-2-oxo-bicyclo- [2.2.1] -hept-1-yl group, in which said substituents, if they are present, they are identical or different and are selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a formyl group, a phenyl group, a phenoxy group, a phenoxy group replaced by bromine at position 4 and a methylsulfonyl group. 15. Compounds, according to one or more of claims 1-14 of general formula I,
15. I in which R1 represents a phenyl group, which is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cx-6 alkyl , linear or branched Cx-6 alkoxy, - (C = 0) -H, -OH, -CF3, -OCF3, -CN and -COOH, R2 represents a phenyl group, which is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cx-6 alkyl, linear or branched Cx-6 alkoxy, - (C = 0) -H, -OH, -CF3, -OCF3, -CN and -COOH, R3 represents a linear or branched, unsubstituted Cx.6 alkyl group, R4 represents a hydrogen atom, -CN, -COOH, a linear Cx_6 alkyl group or unsubstituted branched, or a phenyl group, wherein said phenyl is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, or linear Cx_6 alkyl or branched, linear or branched Cx.6 alkoxy, - (C = 0) -H, -OH, -CF3, -OCF3, -CN and -COOH, R5 represents a group -0-S02-R6, a group -NH- CO-R7, a group -NH2, a group -NH-S02-R8, or a group -NR9-S02-R10 or a group -OC (= 0) -R11, R6 represents a phenyl ring, which is unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cx_6 alkyl, linear or branched Cx-6 alkoxy, - (C = 0) -H , -OH, -CF3, -OCF3, -CN and -COOH, R7 represents a linear or branched Cx.5 alkyl group, wherein said Cx-5 alkyl group is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, -SH, linear or branched Cx_6 alkoxy, - CF3 and -OCF3; a cyclopentyl or cyclohexyl group, wherein said cyclopentyl or cyclohexyl group is unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, -SH , linear or branched Cx-6 alkoxy, -CF3 and -OCF3; or a phenyl group, wherein said phenyl group is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cx_6 alkyl, linear Cx_6 alkoxy or branched, - (C = 0) -H, -OH, -CF3, -0CF3, -CN and -COOH, R8 represents a linear or branched Cx-.5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1,3-benzothiodiazolyl, benzo [b] thiophenyl, benzo [b] furanyl, imidazo [2, lb] thiazolyl and pyrazolyl, wherein said aryl or heteroaryl group is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, straight or branched Cx_6 alkyl, CX alkoxy 6 linear or branched, phenyl (optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, linear or branched CX-6 alkyl and Cx-alkoxy 6 linear or branched), phenoxy (optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, linear or branched Cx_6 alkyl and Cx.6 alkoxy linear or branched), S02-CH3, - (C = 0) -H, -OH, -CF3, -0CF3, -CN and -COOH and said aryl or heteroaryl group is optionally linked via a group to C3.3; or a cyclohexyl group, wherein said cyclohexyl group is optionally linked via a Cx_3 alkylene group in the form of a bridge and / or is linked via a linear or branched Cx_3 alkylene group in the form of a bridge and is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cx-6 alkyl, linear or branched Cx-6 alkoxy, - (C = 0) -H, -OH, -CF3, = 0, -0CF3, -CN and -COOH; R9 represents a group -S02-R12; a group - (C = 0) -R13; a linear or branched Cx_6 alkyl group; or a phenyl radical, wherein said phenyl radical is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cx-6 alkyl, linear or branched Cx_6 alkoxy, - (C = 0) -H, -OH, -CF3, -OCF3, -CN and -COOH and / or said phenyl radical is linked via a Cx_3 alkylene group in the form of a bridge; R10 represents a Cx-linear or branched alkyl; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1,3-benzothiodiazolyl, benzo [b] thiophenyl, benzo [b] furanyl, imidazo [2, lb] thiazolyl and pyrazolyl, wherein said aryl or heteroaryl group is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched CX-6 alkyl, alkoxy Linear or branched Cx_6, phenyl (optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, linear or branched Cx "6 alkyl, and linear Cx_6 alkoxy or branched), phenoxy (optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, straight or branched Cx.6 alkyl and straight or branched Cx-6 alkoxy), S02-CH3, - (C = 0) -H, -OH, -CF3, -0CF3, -CN and -COOH and said aryl or heteroaryl group is optionally linked via a CX-3 alkylene group; or a cyclohexyl group, wherein said cyclohexyl group is optionally linked via a Cx-3 alkylene group in bridged form and / or is linked via a linear or branched Cx-3 alkylene group in bridged form and is unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, straight or branched Cx_6 alkyl, straight or branched Cx_6 alkoxy, - (C = 0) -H, -OH, -CF3, = 0, -0CF3, -CN and -COOH; R11 represents a linear or branched CX-5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1,3-benzothiodiazolyl, benzo [b] thiophenyl, benzo [b] furanyl, imidazo [2, lb] thiazolyl and pyrazolyl, wherein said aryl or heteroaryl group is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cx_6 alkyl, linear Cx_6 alkoxy or branched, phenyl (optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, linear or branched Cx-6 alkyl and linear Cx-6 alkoxy or branched), phenoxy (optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, linear or branched C x 6 alkyl, and C x 6 alkoxy linear or branched), S02-CH3, - (C = 0) -H, -OH, -CF3, -OCF3, -CN and -COOH and said aryl or heteroaryl group is optionally linked via a group Cx-3 alkylene; or a cyclohexyl group, in which said cyclohexyl group is optionally linked via a Cx-3 alkylene group in bridging form and / or is linked via a linear or branched Cx_3 alkylene group in bridged form and is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, straight or branched Cx_6 alkyl, straight or branched Cx_6 alkoxy, - (C = 0) -H, -OH, -CF3 , = 0, -0CF3, -CN and -COOH; R12 represents a linear or branched Cx_5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1,3-benzothiodiazolyl, benzo [b] thiophenyl, benzo [b] furanyl, imidazo [2, lb] thiazolyl and pyrazolyl, wherein said aryl or heteroaryl group is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cx_6 alkyl, linear Cx_6 alkoxy or branched, phenyl (optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, linear or branched Cx_6 alkyl and linear or branched Cx.6 alkoxy ), phenoxy (optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, linear or branched Cx_6 alkyl and straight or branched Cx_6 alkoxy), S02 -CH3, - (C = 0) -H, -OH, -CF3, -OCF3, -CN and -COOH and said aryl or heteroaryl group is optionally linked via a group alkylene Cx_3; or a cyclohexyl group, wherein said cyclohexyl group is optionally linked via a Cx_3 alkylene group in the form of a bridge and / or is linked via a linear or branched Cx_3 alkylene group in the form of a bridge and is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cx_6 alkyl, linear or branched Cx-6 alkoxy, - (C = 0) -H, -OH, -CF3 , = 0, -OCF3, -CN and -COOH; R13 represents a linear or branched Cx_5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1,3-benzothiodiazolyl, benzo [b] thiophenyl, benzo [b] furanyl, imidazo [2, lb] thiazolyl and pyrazolyl, wherein said aryl or heteroaryl group is unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cx-6 alkyl, linear or branched Cx-6 alkoxy, phenyl (optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, linear or branched Cx_6 alkyl and straight or branched Cx_6 alkoxy), phenoxy (optionally substituted with 1, 2 or , 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, straight or branched Cx_6 alkyl and straight or branched CX-S alkoxy), S02-CH3, - (C = 0 ) -H, -OH, -CF3, -OCF3, -CN and -COOH and said aryl or heteroaryl group is optionally linked via an alkylene group Cx_3; or a cyclohexyl group, wherein said cyclohexyl group is optionally linked via a Cx_3 alkylene group in bridging form and / or is linked via a linear or branched Cx-3 alkylene group in the bridged form and is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, straight or branched Cx_6 alkyl, straight or branched Cx_6 alkoxy, - (C = 0) -H, -OH, -CF3 , = 0, -0CF3, -CN and -COOH; optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any mixture ratio, or one of its N-oxides corresponding ones, one of its corresponding salts, or one of its corresponding solvates. 16. Compounds according to one or more of claims 1-15 of general formula I, wherein X represents a halogen atom, preferably a chlorine atom, R5 represents a group -0-S02-R6, a group -NH-CO-R7, a group -NH2, a group -NH-S02-R8, or a group -NR9-S02-R10 or a group -OC (= 0) -R11, R6 represents a phenyl ring, which is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cx-6 alkyl, linear or branched Cx-6 alkoxy, - (C = 0) -H, -OH, -CF3, -OCF3, -CN and -COOH, R7 represents a linear or branched Cx-5 alkyl group, wherein said CX-5 alkyl group is unsubstituted or substituted with 1, 2, 3, 4 or 5 independently selected substituents from the group consisting of F, Cl, Br , -OH, -SH, linear or branched Cx-6 alkoxy, -CF3 and -OCF3; a cyclopentyl or cyclohexyl group, wherein said cyclopentyl or cyclohexyl group is unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, -SH , linear or branched Cx_6 alkoxy, -CF3 and -OCF3; or a phenyl group, wherein said phenyl group is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cx_6 alkyl, linear Cx_6 alkoxy or branched, - (C = 0) -H, -OH, -CF3, -0CF3, -CN and -COOH, R8 represents a linear or branched Cx.sub.x alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1,3-benzothiodiazolyl, benzo [b] thiophenyl, benzo [b] furanyl, imidazo [2, lb] thiazolyl and pyrazolyl, wherein said aryl or heteroaryl group is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, straight or branched Cx.6 alkyl, alkoxy Linear or branched Cx-6, phenyl (optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, linear or branched CX-6 alkyl and alkoxy Linear or branched Cx_6), phenoxy (optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, linear or branched Cx_6 alkyl and linear Cx_6 alkoxy or branched), S02-CH3 / - (C = 0) -H, -OH, -CF3, -OCF3, -CN and -COOH and said aryl or heteroaryl group is optionally linked via a group to the C3_3; or a cyclohexyl group, wherein said cyclohexyl group is optionally linked via a Cx_3 alkylene group in the form of a bridge and / or is linked via a linear or branched Cx_3 alkylene group in the form of a bridge and is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cx-6 alkyl, linear or branched Cx-6 alkoxy, - (C = 0) -H, -OH, -CF3, = 0, -0CF3, -CN and -COOH; R9 represents a group -S02-R12; a group - (C = 0) -R13; a linear or branched Cx_6 alkyl group; or a phenyl radical, wherein said phenyl radical is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, straight or branched Cx_6 alkyl, CX alkoxy -6 linear or branched, - (C = 0) -H, -OH, -CF3, -0CF3, -CN and -COOH and / or said phenyl radical is linked via a Cx_3 alkylene group in the form of a bridge; R10 represents a linear or branched Cx_5 alkyl; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1,3-benzothiodiazolyl, benzo [b] thiophenyl, benzo [b] furanyl, imidazo [2, lb] thiazolyl and pyrazolyl, wherein said aryl or heteroaryl group is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, straight or branched Cx_6 alkyl, Cx alkoxy 6 linear or branched, phenyl (optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, linear or branched Cx.6 alkyl and linear Cx_6 alkoxy or branched), phenoxy (optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, linear or branched Cx_6 alkyl and straight or branched Cx_6 alkoxy) , S02-CH3, - (C = 0) -H, -OH, -CF3, -OCF3, -CN and -COOH and said aryl or heteroaryl group is optionally linked via a group to Cx_3; or a cyclohexyl group, in which said cyclohexyl group is optionally linked via a Cx_3 alkylene group in bridging form and / or is linked via a straight or branched C3_3 alkylene group in bridged form and is unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cx_6 alkyl, linear or branched Cx_6 alkoxy, - (C = 0) -H, -OH, -CF3, = 0, -0CF3, -CN and -COOH; R11 represents a linear or branched Cx-5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1,3-benzothiodiazolyl, benzo [b] thiophenyl, benzo [b] furanyl, imidazo [2, lb] thiazolyl and pyrazolyl, wherein said aryl or heteroaryl group is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched CX-6 alkyl, alkoxy Linear or branched C ,_6, phenyl (optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, linear or branched Cx_6 alkyl and linear Cx_6 alkoxy or branched), phenoxy (optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, linear or branched Cx_6 alkyl and linear Cx-6 alkoxy or branched), S02-CH3, - (C = 0) -H, -OH, -CF3, -OCF3, -CN and -COOH and said aryl or heteroaryl group is optionally linked via a group alkylene Cx_3; or a cyclohexyl group, in which said cyclohexyl group is optionally linked via a Cx_3 alkylene group in bridging form and / or is linked via a straight or branched C3_3 alkylene group in bridged form and is unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cx_6 alkyl, linear or branched Cx_6 alkoxy, - (C = 0) -H, -OH, -CF3, = 0, -0CF3, -CN and -COOH; R12 represents a linear or branched Cx_5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1,3-benzothiodiazolyl, benzo [b] thiophenyl, benzo [b] furanyl, imidazo [2, lb] thiazolyl and pyrazolyl, wherein said aryl or heteroaryl group is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, straight or branched Cx_6 alkyl, Cx alkoxy 6 linear or branched, phenyl (optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, linear or branched Cx_6 alkyl and straight or branched Cx_6 alkoxy ), phenoxy (optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, linear or branched Cx_6 alkyl and straight or branched Cx_6 alkoxy), S02 -CH3, - (C = 0) -H, -OH, -CF3, -0CF3, -CN and -COOH and said aryl or heteroaryl group is optionally linked via a group to lkylene Cx_3; or a cyclohexyl group, in which said cyclohexyl group is optionally linked via a Cx-3 alkylene group in bridging form and / or is linked via a linear or branched Cx_3 alkylene group in bridged form and is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cx-6 alkyl, straight or branched Cx.6 alkoxy, - (C = 0) -H, - OH, -CF3, = 0, -0CF3, -CN and -COOH; R13 represents a linear or branched Cx.sub.x alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1,3-benzothiodiazolyl, benzo [b] thiophenyl, benzo [b] furanyl, imidazo [2, lb] thiazolyl and pyrazolyl, wherein said aryl or heteroaryl group is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cx_6 alkyl, linear or branched Cx_6 alkoxy, phenyl (optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, linear or branched Cx_6 alkyl and linear Cx_6 alkoxy or branched), phenoxy (optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, linear or branched Cx_6 alkyl and linear Cx.6 alkoxy or branched), S02-CH3, - (C = 0) -H, -OH, -CF3, -OCF3, -CN and -COOH and said aryl or heteroaryl group is optionally linked via an alkylene group Cx_3; or a cyclohexyl group, wherein said cyclohexyl group is optionally linked via a Cx-3 alkylene group in bridged form and / or is linked via a linear or branched Cx-.3 alkylene group in bridged form and is unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, straight or branched Cx_6 alkyl, straight or branched Cx_6 alkoxy, - (C = 0) -H, - OH , -CF3, = 0, -OCF3, -CN and -COOH; optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any mixture ratio, or one of its N-oxides corresponding ones, one of its corresponding salts, or one of its corresponding solvates. 17. Compounds according to one or more of claims 1-16 of general formula I, wherein R1 represents a phenyl group, which is monosubstituted by a halogen atom, preferably a chlorine atom, at the 4-position of the phenyl ring, R2 represents a phenyl group, which is monosubstituted by a halogen atom, preferably an atom of chlorine, in the 4-position of the phenyl ring, R3 represents a linear or branched, unsubstituted Cx-.6 alkyl group, preferably a methyl group, R4 represents a hydrogen atom, R5 represents a group -0-S02-R6, a group -NH-CO-R7, a group -? H2, a group -? H-S02-R8, or a group -? R9-S02-R10 R6 represents a phenyl ring, which is optionally substituted by one or more atoms of halogen, preferably one or more fluorine atoms and / or one or more chlorine atoms, R7 represents a linear or branched Cx_5 alkyl group, a linear or branched Cx_5 alkyl group, which is at least partially fluorinated, a C3- cycloalkyl group 8, or a phenyl group, which is optionally substituted by a or more halogen atoms, preferably one or more fluorine atoms, R8 represents a linear or branched Cx_5 alkyl group, a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of an fluorine, a chlorine atom, an unsubstituted phenyl group, a formyl group, a methylsulfonyl group, a benzyl group and a phenoxy group, which is optionally monosubstituted by a bromine atom in its 4-position, a naphthyl group, which can be linked via a methylene or ethylene group, a benzo [b] thiophene group, which is optionally substituted by one or more methyl groups and / or one or more chlorine atoms, a pyrazole group, which is optionally substituted by one or more substituents independently selected (s) of the group consisting of a methyl group, an ethyl group and a phenyl group, an imidazo [2, lb] thiazole group, which is optionally substituted by one or more chloro atoms or, a thienyl group, a furyl group, a 2,1,3-benzothiadiazole group, a 7,7-dimethyl-2-oxo-bicyclo- [2.2.1] -hept-1-yl group, or a benzyl group , R9 represents a CX-5 alkyl group, preferably a methyl group, a phenyl group, which is optionally substituted by one or more fluorine atoms and / or one or more chlorine atoms, a benzyl group, in which the ring is optionally substituted by one or more fluorine atoms and / or one or more chlorine atoms, or a group -S02-R12, R10 represents a phenyl group, which is optionally substituted by one or more fluorine atoms and / or one or more chlorine atoms, R12 represents a Cx_5 alkyl group, preferably a methyl group, or a phenyl group, which is optionally substituted by one or more fluorine atoms and / or one or more chlorine atoms, optionally in the form of one of its stereoisomers , preferably enantiomers or diastereomers, their racemate or in the form of a mixture of at least two of their stereoisomers, p preferably enantiomers and / or diastereomers, in any mixture ratio, or one of its corresponding N-oxides, one of its corresponding salts, or one of its corresponding solvates. 18. Compounds according to one or more of claims 1-17, selected from the group consisting of [1] Ester of 4-fluoro-benzenesulfonic acid 1- [bis- (4-chloro-phenyl) -methyl] -trans -2-methyl-3-azetidinol, [2] N-. { (2S, 3R) -1- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} -2,2,2-trifluoroacetamide, [3] (2S, 3R) -1- [Bis- (4-chloro-phenyl) -methyl] -2-methyl-3-aminoazetidine, [4] Amide. { l- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} of hexanoic acid, [5] N-. { (2S, 3R) -1- [Bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} -4-fluoro-benzenesulfonamide, [6] Amide. { (2S, 3R) -1- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} of 2-thiophenesulfonic acid [7] Amide. { (2S, 3R) -1- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} of cyclohexanecarboxylic acid, [8] Amide. { (2S, 3R) -1- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} of butan-1-sulfonic acid, [9] N-. { (2S, 3R) -1- [Bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} -3,5-difluoro-benzamide, [10] Amide. { trans-1- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} of naphthalene-2-sulfonic acid, [11] Amide. { trans-1- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} of biphenyl-4-sulfonic acid, [12] 4-Acetyl-N-. { trans-l- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} -benzenesulfonamide, [13] N-. { trans-l- [Bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} -4- (4-bromo-phenoxy) -benzenesulfonamide, [14] N-. { trans-l- [Bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} -4-methylsulfonyl-benzenesulfonamide, [15] Amide. { trans-1- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} of 2, 1, 3-benzothiadiazole-4-sulphonic acid, [16] Amide. { trans-1- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} of 5-chloro-3-methyl-benzo [b] thiophene-2-sulfonic acid, [17] Amide. { trans-1- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} of 6-chloro-imidazo [2, 1-b] thiazole-5-sulfonic acid, [18] N-. { trans-1- [Bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} -3,5-dichloro-benzenesulfonamide, [19] Amide. { trans-1- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} of 2-naphthalene-l-yl-ethanesulfonic acid, [20] N-. { trans-l- [Bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} phenyl-methylsulfonamide, [21] N-. { trans-1- [Bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} - (7,7-dimethyl-2-oxo-bicyclo [2.2.1] hept-1-yl) -methylsulfonamide, [22] Amide. { trans-1- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} of naphthalene-1-suifonic acid, [23] N-. { trans-1- [Bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} -4-phenoxy-benzenesulfonamide, [24] Amide. { trans-1- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} of 1,3,5-trimethyl-lH-pyrazol-4-sulfonic acid, [25] Amide. { trans-1- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} of benzo [b] thiophene-3-sulfonic acid, [26] Amide. { trans-1- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} of 5-methyl-1-phenyl-1H-pyrazole-4-sulfonic acid, [27] N-. { trans-l- [Bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} -N-methyl-4-fluoro-benzenesulfonamide, [28] N-. { trans-l- [Bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} -N- (4-fluoro-benzyl) -4-fluorobenzenesulfonamide, [29] N-. { trans-l- [Bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} -N-propyl-4-fluoro-benzenesulfonamide, [30] N-. { trans-l- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} -N- (methylsulfonyl) -4-fluorobenzenesulfonamide, [31] N-. { trans-l- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} -N-bis (4-fluoro-benzenesulfonamide), [32] N-. { (trans-1- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} -4-fluoro-benzenesulfonamide, and [33] N-. {(2R, 3S) -1- [bis- (4-chloro-phenyl) -methyl] -2-methyl-azetidin-3-yl} -4-fluoro-benzenesulfonamide optionally in the form of an N-oxide, a corresponding salt or a corresponding solvate 19. Process for the preparation of substituted azetidine compounds according to one or more of claims 1-18, characterized in that at least one compound of general formula II
16. II in which R1 to R4 have the meaning according to one or more of claims 1-18, reacts with at least one compound of general formula Xx-S02-R6 or X2-CO-R11, in which R6 and R11 they have the meaning according to one or more of claims 1-18 and X1 and X2 are leaving groups, in a reaction medium, optionally in the presence of at least one base, to obtain at least one compound of general formula I according to with claim 1, wherein R5 represents a group -O-S02-R6 or a group -O-CO-R11, and optionally purifying and / or optionally isolating said compound (s), and optionally at least one of the compounds mentioned above, in which R5 represents a group -0-S02-R6 or a group -O-CO-R11, reacts with ammonia to obtain a compound of general formula I according to claim 1, wherein R5 represents a group -NH2, and optionally purifying and / or optionally isolating said compound (s), and optionally Finally, at least one of the compounds mentioned above, in which R 5 represents a group -NH 2, reacts with at least one compound of the general formula X 3 -COR 7, X 4 -S0 2 -R 8 or X 5 -S0 2 -R 10, in which R 7, R8 and R10 have the meaning according to one or more of claims 1-17 and X3, X4 and X5 represent leaving groups, in a reaction medium, optionally in the presence of at least one base, to obtain a compound of general formula I according to claim 1, wherein R5 represents a group -NH-CO-R7, a group -NH-S02-R8, or a group -NR9-S02-R10 with R9 representing a hydrogen atom, and optionally purifying and / or optionally isolating said compound (s), and optionally at least one compound of general formula I, wherein R5 represents a group -NR9-S02-R10 with R9 representing a hydrogen atom, reacts with minus a compound of general formula X6-R9, in which R9 has the meaning according to one or more of the claims 1-18 with the exception of a hydrogen atom, and X6 represents a leaving group, to obtain at least one compound of general formula I according to claim 1, wherein R5 represents a group -NR9-S02- R10, and optionally purifying and / or optionally isolating said compound (s), or, that at least one compound of general formula
17. III,
18. III in which R1-R3 have the meaning according to one or more of claims 1-18, is oxidized to obtain at least one compound of general formula IV,
19. IV in which Ril-pR33 have the meaning according to one or more of claims 1-18, which is optionally purified and / or optionally isolated, and reacts with at least one compound of general formula R5aH, in which R5a represents a group -NH2 or a group -NHR9, in which R9 has the meaning indicated above, the resulting compound is optionally purified and / or optionally isolated and optionally reacts with at least one compound of general formula X3-CO-R7, X4- S02-R8 or X5-S02-R10, in which R7, R8 and R10 have the meaning indicated above and X3, X4 and X5 represent leaving groups, in a reaction medium, optionally in the presence of at least one base, to obtain a compound of general formula I according to one or more of claims 1-18, wherein R5 represents a group -NH2, a group -NH-CO-R7, a group -NH-S02-R8, or a group -NR9-S02-R10, which is optionally purified and / or isolated. 20. Process for the preparation of substituted azetidine compounds according to one or more of claims 1-18, characterized in that at least one compound of general formula V, v in which Y represents a halogen atom, preferably a chlorine atom or a bromine atom, and R1 and R2 have the meaning according to one or more of claims 1-18, reacts with at least one compound of formula General VI,
20. VI optionally in the form of a salt, in which R3, R4 and R5 have the meaning according to one or more of claims 1-18, in a suitable reaction medium, optionally in the presence of a base, and the the resulting azetidine compound (s) is / are optionally purified (s) and / or optionally isolated (s).
21. 21. A medicament comprising at least one substituted azetidine compound according to one or more of claims 1-18 including the non-claimed compounds and optionally one or more pharmaceutically acceptable excipients.
22. 22. Medicament according to claim 21 for the modulation of cannabinoid receptors, preferably cannabinoid receptors 1 (CBX), for the prophylaxis and / or treatment of disorders of the central nervous system, disorders of the immune system, disorders of the cardiovascular system, disorders of the endocrine system, disorders of the respiratory system, disorders of the gastrointestinal tract or disorders of reproduction.
23. 23. Medication according to claim 21 or 22 for the prophylaxis and / or treatment of the dysfunctions of food intake, preferably selected from the group consisting of bulimia, anorexia, cachexia, obesity and type II diabetes mellitus (diabetes mellitus not insulin-dependent), more preferably obesity.
24. 24. Medication according to claim 21 or 22 for the prophylaxis and / or treatment of psychosis.
25. 25. Medication according to claim 21 or 22 for the prophylaxis and / or treatment of the abuse and / or addiction of alcohol, abuse and / or nicotine addiction, abuse and / or drug addiction and / or abuse and / or addiction of medications, preferably drug abuse and / or addiction.
26. 26. Medicament according to claim 21 or 22 for the prophylaxis and / or treatment of one or more disorders selected from the group consisting of schizophrenia, anxiety, depression, epilepsy, neurodegenerative disorders, cerebellar disorders, spinocerebellar disorders, cognitive disorders, trauma Cranial, Panic Attacks, Peripheral Neuropathy, Glaucoma, Migraine, Parkinson's Morbus, Huntington's Morbus, Alzheimer's Morbus, Raynaud's Disease, Tremors, Compulsive Disorders, Senile Dementia, Thymic Disorders, Late Oral Dyskinesia, Bipolar Disorders, Cancer, Induced Movement Disorders due to medications, dystonia, endotoxemic shock, hemorrhagic shock, hypotension, insomnia, immunological disorders, sclerotic plaques, vomiting, diarrhea, asthma, memory disorders, pruritus, pain or for the potentiation of the analgesic effect of narcotic and non-narcotic analgesics, or to influence intestinal transit.
27. 27. Use of at least one substituted azetidine compound according to one or more of claims 1-18 including the non-claimed compounds and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the modulation of cannabinoid receptors, preferably cannabinoid receptors 1 (CBX), for the prophylaxis and / or treatment of disorders of the central nervous system, disorders of the immune system, disorders of the cardiovascular system, disorders of the endocrine system, disorders of the respiratory system, disorders of the gastrointestinal tract or disorders of the reproduction.
28. 28. Use of at least one substituted azetidine compound according to one or more of claims 1-18 including the non-claimed compounds and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the prophylaxis and / or treatment of dysfunctions of food intake, preferably selected from the group consisting of bulimia, anorexia, cachexia, obesity and diabetes mellitus type II (non-insulin-dependent diabetes mellitus), more preferably obesity.
29. 29. Use of at least one substituted azetidine compound according to one or more of claims 1-18 including the non-claimed compounds and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the prophylaxis and / or treatment of psychosis
30. 30. Use of at least one substituted azetidine compound according to one or more of claims 1-18 including the non-claimed compounds and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the prophylaxis and / or treatment of abuse and / or addiction of alcohol, abuse and / or nicotine addiction, abuse and / or drug addiction and / or abuse and / or drug addiction, preferably drug abuse and / or addiction.
31. 31. Use of at least one substituted azetidine compound according to one or more of claims 1-18 including the non-claimed compounds and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the prophylaxis and / or treatment of one or more disorders selected from the group consisting of schizophrenia, anxiety, depression, epilepsy, neurodegenerative disorders, cerebellar disorders, spinocerebellar disorders, cognitive disorders, cranial trauma, panic attacks, peripheral neuropathy, glaucoma, migraine, Morbus Parkinson, Morbus Huntington, Morbus Alzheimer , Raynaud's disease, tremors, compulsive disorders, senile dementia, thymic disorders, late oral dyskinesia, bipolar disorders, cancer, drug-induced movement disorders, dystonia, endotoxemic shock, hemorrhagic shock, hypotension, insomnia, immune disorders, sclerotic plaques, vomiting, diarrhea, a sma, memory disorders, pruritus, pain, or for the enhancement of the analgesic effect of narcotic and non-narcotic analgesics, or to influence intestinal transit.